

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/000020

International filing date: 18 January 2005 (18.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/538,342
Filing date: 22 January 2004 (22.01.2004)

Date of receipt at the International Bureau: 21 February 2005 (21.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

17248-07

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 10, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/538,342

FILING DATE: *January 22, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/00020*



Certified by

Don W. Duckas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office




012204

15866 U.S. PTO

Modified PTO/SB/16 (6-95)
Approved for use through 04/11/98. OMB 0651-0037
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c)

Docket Number		P-16604		Type a plus sign (+) inside this box -->	+
INVENTOR(S)/APPLICANT(S)					
LAST NAME	FIRST NAME	MIDDLE NAME	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)		
Wallace	Owen	Brendan	Zionsville, Indiana		
Dodge	Jeffrey	Alan	Indianapolis, Indiana		
Dally	Robert	Dean	Indianapolis, Indiana		
Shepherd	Timothy	Alan	Indianapolis, Indiana		
TITLE OF THE INVENTION (280 characters max)					
SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS					
CORRESPONDENCE ADDRESS					
Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288			 25885 PATENT TRADEMARK OFFICE		
STATE	IN	ZIP CODE	46206-6288	COUNTRY	USA
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification	Number of pages	73	<input type="checkbox"/> Small Entity Statement		
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (Specify)		
METHOD OF PAYMENT (check one)					
<input type="checkbox"/> A check or money order is enclosed to cover the Provisional filing fees				PROVISIONAL FILING FEE AMOUNT (\$)	\$160.00
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number:	05-0840				

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.☐ Yes, the name of the U.S. Government agency and the Government contract number are:Respectfully submitted,
SIGNATURE

GILBERT T. VOY

Date 01 / 22 / 04

REGISTRATION NO.
(if appropriate)

43,972

TYPED or PRINTED NAME

☐ Additional inventors are being named on separately numbered sheets attached hereto**PROVISIONAL APPLICATION FOR PATENT FILING ONLY**

"Express Mail" mailing label number	EL 832896798 US	Date of Deposit	1-22-04
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.			
GILBERT T. VOY		Signature	
Printed Name			

SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS

Background of the Invention

5

"Vasomotor symptoms", i.e., hot flashes, night sweats, vaginal dryness, sleep disturbances, nausea and mood swings commonly affect women around menopause. In fact, a majority of postmenopausal women will experience vasomotor symptoms with a significant percentage of these women continuing to suffer symptoms for more than five years (Psychosom. Med. 1965, 27, 266; Med. Gynecol. Soc. 1969, 4, 268). Women who have undergone bilateral oophorectomy, radiotherapy or treatment with GnRH (gonadotropin releasing hormone) agonists are particularly prone to experiencing hot flashes (Br. J. Obstet. Gynaecol. 1977, 84, 769). Men have also been reported to experience vasomotor symptoms following treatment with a GnRH agonist (N. Engl. J. Med. 1981, 305, 663) or after orchidectomy (Urology 1980, 16, 620).

In spite of being identified as an ailment of menopause for hundreds of years, the precise mechanism underlying the cause of vasomotor symptoms is not clear. However, a link with declining estrogen levels (due to natural menopause or otherwise) is widely accepted. Interestingly, women with low estrogen levels due to ovarian dysgenesis generally do not suffer from vasomotor symptoms unless they are first given hormone replacement therapy (HRT) and then have it discontinued (Clin. Endocrinol. (Oxf) 1985, 22, 293), suggesting that *estrogen withdrawal* may be an underlying cause of vasomotor instability. HRT is currently a preferred standard treatment for vasomotor symptoms and is effective in >80% of women who initiate treatment, which again is supportive of an estrogenic role in the etiology thereof.

30	"Express Mail" mailing label number <u>EL 832896798 US</u>
	Date of Deposit <u>1-22-04</u>
	I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
35	<u>DUGEN Thomas</u> <u>Deven Thomas</u> Printed Name Signature

Hot flashes (flushes) are characterised by a warming sensation that begins in the chest and moves towards the neck and head, and are often accompanied by sweating, palpitations and cutaneous flashing. The episodes last from 30 seconds to 10 minutes.

5 The hot flash event itself is thought to be centrally mediated resulting from a transient lowering of the thermoregulatory set point in the hypothalamus (for a review, see: Can. J. Physiol. Pharmacol. 1987, 65, 1312). Regulation of the thermoregulatory process may involve catecholamines, estrogen, testosterone, opioids and serotonin, among others (for a review, see: Mayo. Clin. Proc. 2002, 77, 1207). In fact, compounds that modulate the
10 signaling pathway of each of these hormones/neurotransmitters have been evaluated for the treatment of hot flashes. See, e.g., Ann. Intern. Med. 2000, 132, 788; Br. Med. J. 1974, i, 409; Maturitas, 1978, 1, 21; Med. J. Aust. 1986, 144, 369; Fertil. Steril. 1985, 43, 401; Br. J. Obstet. Gynaecol. 1981, 88, 919; J. Clin. Endocrinol. Metab. 1984, 58, 578; Clin. Endocrinol. 1985, 22, 293; Maturitas 2000, 36, 155; J. Clin. Oncol 2002, 20, 1583;
15 JAMA 2003, 289, 2827; Lancet 2000, 356, 2059; N. Engl. J. Med. 1994, 331, 347; Obstet. Gynecol. 1984, 63, 1; Obstet. Gynecol. 1999, 94, 225; Br. J. Obstet. Gynecol. 1998, 105, 904; Neurology 2000, 54, 2161; Obstet. Gynecol. 1998, 72, 688; J. Clin. Oncol. 1998, 16, 495; J. Clin. Oncol. 2001, 19, 2739; and J. Nutr. 2001, 131 (11, suppl), 3095s.

20 In spite of the apparent large number of treatments for hot flashes, all the current therapies suffer from poor efficacy, are associated with unacceptable side effects or are contraindicated for certain patient populations. For example, HRT is not recommended for women with a history of breast cancer, uterine cancer, ovarian cancer, or venous thromboembolism. Recent data also suggests HRT may not be suitable for women with
25 coronary artery disease. Non-hormonal treatments generally are not fully efficacious (e.g. clonidine) and/or cause adverse effects (e.g., venlafaxine, gabapentin).


Many publications have appeared within the last ten years disclosing selective estrogen receptor modulators (SERMs), e.g., U.S. Patent No.'s 5,484,795, 5,484,798, 5,510,358, 5,998,401 and WO 96/09040. Many of these SERMs, generally speaking,
30 have been found to have a beneficial estrogen agonist activity in the bone and cardiovascular systems with a concomitant beneficial estrogen antagonist activity in the breast. A small, particularly useful subset of such compounds has also been found to have

an estrogen antagonist effect or to have a non-estrogenic effect in the uterus. However, the actual use of a SERM in the treatment of vasomotor symptoms has also been hampered by problems with efficacy, *e.g.*, during Phase III clinical studies of raloxifene for the treatment/prevention of post-menopausal osteoporosis, raloxifene was associated with a slight increased incidence of hot flash compared to placebo and tamoxifen is known to induce hot flashes in more than 50% of patients (Arch. Intern. Med. 1991, 151, 1842).

There, therefore, remains an unmet medical need for vasomotor symptom therapies that overcome the liabilities of current treatments. In particular, there is a need for a medication that possesses the positive attributes of previously disclosed SERMs such as raloxifene (*i.e.*, positive effects on bone, uterus, breast and cardiovascular system) but also alleviates vasomotor symptoms.

Summary of Invention

The present invention relates to a compound of formula I:



wherein:

- m is 0, 1 or 2;
- n is 1, 2, 3, 4 or 5;
- R is H or methyl provided that if m is 1 or 2, then R must be H and that if m is 0, then R must be methyl;
- R¹ is H, SO₂(n-C₄-C₆ alkyl) or COR²;
- X is O or NR³;
- X¹ is O, CH₂ or C=O;

R^2 is C_1 - C_6 alkyl; C_1 - C_6 alkoxy; NR^4R^{4a} ; phenoxy; or phenyl optionally substituted with halo;

R^3 is H or C_1 - C_6 alkyl; and


R^4 and R^{4a} are independently H, C_1 - C_6 alkyl or phenyl; or a
5 pharmaceutical acid addition salt thereof.

The present invention also relates to a pharmaceutical composition that comprises a compound of formula I, or a pharmaceutical acid addition salt thereof, and a pharmaceutical carrier. In another embodiment, the pharmaceutical composition of the present invention may be adapted for use in treating one or more vasomotor symptoms.

10 The present invention also relates to methods for treating one or more vasomotor symptoms employing a compound of formula I, or a pharmaceutical acid addition salt thereof.

In addition, the present invention relates to a compound of formula I, or a pharmaceutical acid addition salt thereof, for use in treating one or more vasomotor
15 symptoms. The present invention is further related to the use of a compound of formula I, or a pharmaceutical acid addition salt thereof, for the manufacture of a medicament for treating one or more vasomotor symptoms.

The present invention also relates to a compound of formula II:



20 II;

or an acid addition salt thereof; wherein m , n , R and X^1 are as defined above for a formula I compound and:

R^{1a} is H, SO_2CH_3 , $SO_2(n-C_4-C_6 \text{ alkyl})$, COR^2 , C_1 - C_6 alkyl or benzyl;

X^2 is O or NR^5 ; and

R^5 is H, C_1 - C_6 alkyl or $CO_2(C_1$ - C_6 alkyl); provided that if R^{1a} is H, $SO_2(n$ - C_4 - C_6 alkyl) or COR^2 , then X^2 is NR^5 and R^5 is $CO_2(C_1$ - C_6 alkyl); useful as an intermediate to a compound of formula I.

5

Detailed Description

Unless specified otherwise, reference hereafter to "a compound of formula I" includes the pharmaceutical acid addition salts thereof.

The compounds of the present invention have one or more chiral centers and may exist in a variety of stereoisomeric configurations. As a consequence of these chiral
10 centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of the present invention.

For the purposes of the present invention, as disclosed and claimed herein, the
15 following terms are defined below.

The term "halo" refers to fluoro, chloro, bromo and iodo. The term " C_1 - C_6 alkyl" represents a straight, branched or cyclic hydrocarbon moiety having from one to six carbon atoms, *e.g.*, methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, isobutyl, sec-butyl, *t*-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl and the like. Moieties
20 such as a cyclobutylmethylenyl and cyclopropylmethylenyl are also included within the scope of a C_1 - C_6 alkyl group. The term " C_1 - C_4 alkyl" refers specifically to methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, isobutyl, sec-butyl, *t*-butyl, cyclopropylmethyl and cyclobutyl. The term "*n*- C_4 - C_6 alkyl" refers specifically to *n*-butyl, *n*-pentyl and *n*-hexyl. A " C_1 - C_6 alkoxy" group is a C_1 - C_6 alkyl moiety connected
25 through an oxy linkage.

The term "pharmaceutical" when used herein as an adjective means substantially non-deleterious.

A pharmaceutical "acid addition salt" is a salt formed by reaction of the free base form of a compound of formula I with a pharmaceutical acid, such as described in the
30 Encyclopedia of Pharmaceutical Technology, editors James Swarbrick and James C. Boylan, Vol 13, 1996 "Preservation of Pharmaceutical Products to Salt Forms of Drugs

and Absorption". Specific salt forms include, but are not limited to the: acetate, benzoate, benzenesulfonate, 4-chlorobenzenesulfonate; citrate; ethanesulfonate; fumarate; d-gluconate; d-glucuronate; glutarate; glycolate; hippurate; hydrochloride; 2-hydroxyethanesulfonate; dl-lactate; maleate; d-malate; l-malate; malonate; d-mandelate; l-mandelate; methanesulfonate; 1,5 naphthalenedisulfonate; 2-naphthalenesulfonate; phosphate; salicylate; succinate; sulfate; d-tartrate; l-tartrate; and p-toluenesulfonate.

The terms "treating" and "treat" as used herein, means alleviating, ameliorating, preventing, prohibiting, restraining, slowing, stopping, or reversing the progression or severity of a pathological condition, or sequela thereof, described herein. The term "preventing" means reducing the likelihood that the recipient of a compound of formula I will incur, further incur or develop any of the pathological conditions, or sequela thereof, described herein.

The term "vasomotor symptom" is a condition selected from the list of: hot flash, night sweats, vaginal dryness, sleep disturbances, nausea and mood swings; wherein said condition results from a decrease of circulating endogenous estrogen that occurs in a woman following cessation or reduction of menstruation due to natural, surgical, or other processes.


The term "a woman in need thereof" is a woman either suffering from the claimed pathological condition, or is a woman at a recognized risk thereof, as determined by medical diagnosis, *i.e.*, as determined by the attending physician.

As used herein, the term "effective amount" means an amount of a compound of formula I that is capable of treating the conditions described herein.

Preferred Compounds and Embodiments of the Invention

Certain compounds of the invention are particularly interesting and are preferred. The following listing sets out several groups of preferred compounds. It will be understood that each of the listings may be combined with other listings to create additional groups of preferred compounds. The following numbering system will be used to describe the preferred positions of the fluoro moieties:

-7-




- a) m is 1;
 - b) n is 1, 2, 3 or 4;
 - c) n is 1, 2 or 3;
 - 5 d) n is 1 or 2;
 - e) n is 1;
 - f) n is 2;
 - g) n is 1 and the corresponding fluoro moiety is in the 4-position;
 - h) n is 2 and the corresponding fluoro moieties are in the 3,5-positions;
 - 10 i) R^1 is H;
 - j) R^1 is H or COR^2 and R^2 is C_1 - C_6 alkyl or phenyl;
 - k) R^1 is H or COR^2 and R^2 is C_1 - C_4 alkyl, $NHCH_3$ or phenyl;
 - l) R^3 is H, methyl or ethyl;
 - m) R^3 is H;
 - 15 n) X is O;
 - o) X is NR^3 and R^3 is H or methyl;
 - p) X^1 is O;
 - q) the hydrochloride salt form.
- 20 The compound of formula I is preferably employed in the treatment of hot flashes.
- The compound of formula I is preferably formulated in a dosage unit form, *i.e.*, in an individual delivery vehicle, for example, a tablet or capsule, prior to administration to the recipient woman.
- 25 The compound of formula I is preferably administered orally.

Synthesis

The compound of formula I may be prepared as described in the following Schemes, Preparations and Examples.

5

Scheme 1


In Scheme 1, a compound of formula IV is reacted with a compound of formula III under usual "Suzuki" or "Stille" reaction conditions, *i.e.*, wherein one of substituent "A" or "D" is a boronic acid/ester or alkyl stannane moiety and the other is a leaving group, *e.g.*, chloro, bromo or iodo or a sulfonate group such as trifluoromethyl sulfonate, to provide a compound of formula II. When R^{1a} is SO₂CH₃, C₁-C₆ alkyl or benzyl (preferably methyl, benzyl or SO₂CH₃) said hydroxy protecting groups may be removed under standard conditions (see, *e.g.*, the procedures that follow or the latest edition of Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, N.Y.) to

provide the compound of formula I where R^1 is H. Similarly, when X^2 is NR^5 and R^5 is $CO_2(C_1-C_6 \text{ alkyl})$, said amino protecting group may also be removed as taught in the Greene. A formula I compound where R^1 is H may be further derivatized employing standard acylation or sulfonylation methodology to prepare a compound of formula I where R^1 is COR^2 or $SO_2(n-C_4-C_6 \text{ alkyl})$.

Compounds of formula III may be prepared as shown below or by procedures analogous to those found in the art. Compounds of formula IV are, in general, commercially available or can be prepared by procedures readily available to the ordinarily skilled synthetic organic chemist or as shown below.

Preparation 1

Trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester



Add 6-methoxynaphthalene-2-ol (20 g, 114.8 mmol) to dimethylformamide (DMF, 250 mL) at ambient temperature followed by *N*-bromosuccinimide (NBS, 21.5 g, 120 mmol) over a 30 minute period. After 45 minutes, dilute with water (800 mL), collect and dry the precipitate to provide 25.5 g (87%) of 1-bromo-6-methoxy-naphthalen-2-ol.

Add 1-bromo-6-methoxy-naphthalen-2-ol (66.7 g, 264 mmol), potassium carbonate (K_2CO_3 , 40.0 g, 290 mmol) and benzyl bromide (49.6 g, 290 mmol) to DMF (800 mL). Stir the mixture at ambient temperature for 1 hour. Add water (400 mL) to precipitate the product. Collect the precipitate and wash the filter cake with heptane (3 X 125 mL) then dry to provide 83.7 g of 2-benzyloxy-1-bromo-6-methoxy-naphthalene (86.2%).

Combine toluene (200 mL), 2-benzyloxy-1-bromo-6-methoxy-naphthalene (30 g, 87.4 mmol), 4-(2-piperidin-1-yl-ethoxy)phenol (23.2 g, 105 mmol) and cesium carbonate


(34.4 g, 105 mmol), and heat the mixture to reflux. Remove a portion of the toluene (100 mL). Add ethyl acetate (390 mg, 4.37 mmol) and copper triflate benzene complex (2.20 g, 4.37 mmol) to the reaction mixture and stir for 5 minutes. Remove the solvent by distillation and heat the resulting residue to 174°C for 1.5 hours. Dissolve the residue in a mixture of ethyl acetate (200 mL) and aqueous HCl (1 N, 90 mL). Separate and concentrate the organics to a residue. Column chromatograph the residue to give 12.4 g of 1-{2-[4-(2-benzyloxy-6-methoxy-naphthalen-1-yloxy)-phenoxy]-ethyl}-piperidine (30%).

Add 1-{2-[4-(2-benzyloxy-6-methoxy-naphthalen-1-yloxy)-phenoxy]-ethyl}-piperidine (12.4 g, 25.5 mmol) to a methanol/ethyl acetate mixture (1:1, 490 mL) and heat to form a solution. Remove the heat and add ammonium formate (4.83 g, 76.6 mmol) and Pd(OH)₂ on carbon (20 % ww, 1.58 g, 1.12 mmol). Reflux for 50 minutes then filter the mixture. Concentrate the filtrate to provide 9.9 g of 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalene-2-ol (98.5%).

Cool dichloromethane (290 mL), triethylamine (3.08 g, 30.4 mmol) and 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalene-2-ol (9.2 g, 23.4 g) to -50°C and add trifluoromethane sulfonic acid anhydride (7.26 g, 25.7 mmol). Stir the resulting mixture at -50°C for 2 hours then allow the mixture to warm to ambient temperature before stirring for an additional hour. Add brine (150 mL) and separate the organics. Wash the organics with NaHCO₃ then dry before concentrating to a residue. Crystallize the residue with ethyl ether – hexanes to provide 11.2 g of the title compound (90.9%).

Example 1

1-(2-{4-[2-(2,6-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine



Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (1.0 gm., 1.9 mmoles) in 20 ml DMF. To this solution add 2,6difluorophenylboronic acid (0.6 gm., 3.8 mmoles), potassium phosphate (2.42 gm., 11.4 mmoles) and tetrakis(triphenylphosphine)palladium (0) (0.44 gm., 0.38 mmoles) and heat to 100 °C for 18 hours. Cool and filter the mixture and purify on an SCX column, eluting the impurities with methanol, then eluting the product with 2N ammonia/methanol. Purify further on a silica gel column eluting with a gradient of 50-100% methylene chloride/hexane containing 1% isopropyl amine to give 300 mg (32 %) of the title compound.

10

Example 2

6-(2,6-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride


15

Dissolve 1-(2-{4-[2-(2,6-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine (300 mg., 0.61 mmoles) in 20 ml methylene chloride and chill in ice. To this add 2.0 ml of boron tribromide with swirling and allow to warm to room temperature. Pour this mixture into a two-phase mixture consisting of saturated sodium bicarbonate and a 3/1 mixture of chloroform/isopropanol. Wash the organic layer with brine and dry over 3A molecular sieves. Purify further using reverse phase chromatography to give 138 mg of the title compound (48%). Convert to hydrochloride salt and lyophilize. ¹H-NMR (CDCl₃, 300 MHz) δ 7.92 (d, J = 9.0 Hz, 1H); 7.59 (d, J = 8.4 Hz, 1H); 7.35 (d, J = 8.4 Hz, 1H); 7.20-7.17 (m, 2H); 7.03 (dd, J = 9.0, 2.1 Hz, 1H); 6.85-6.80 (m, 2H); 6.52 (s, 4H); 3.95 (t, J = 5.7 Hz, 2H); 2.73 (t, J = 6.0 Hz, 2H); 2.52-2.52 (m, 4H); 1.64-1.59 (m, 4H); 1.46-1.44 (m, 2H).

25

Example 3

1-(2-{4-[2-(2-Fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine
hydrochloride



5

Charge an oven-dried 100 mL round-bottom flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (300mg, 0.57 mmol.) and place under nitrogen. Dissolve the solid in acetonitrile (10mL) and add 2-fluorophenylboronic acid (240mg, 1.71 mmol), tricyclohexylphosphine (48mg, 0.17 mmol), palladium acetate (38mg, 0.17 mmol), and cesium fluoride (780mg, 5.14 mmol). Bring the solution to 85 °C and stir for 1 hour. Filter the solution over a pad of celite, rinse with acetonitrile and concentrate *in vacuo*. Purify the crude product using radial chromatography to give 295 mg (110%) of the free base of the title compound. Dissolve the free base in 3mL ether and add 0.8 mL of 1N HCl. Immediately dry to give 305 mg of the title compound: mass spectrum (ion spray) $m/z = 472(M-Cl)$.

15

Example 4

6-(2-Fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol
hydrochloride

20


Charge a 100 mL round-bottom flask with 1-(2-{4-[2-(2-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine hydrochloride (290 mg, 0.57 mmol) in 5mL anhydrous CH_2Cl_2 and cool to 0 °C under nitrogen. Add 2.90 mL (2.90 mmol) of a 1M CH_2Cl_2 solution of BBR_3 and monitor the reaction by ES-MS. After stirring for 1 hour, pour the reaction into a cold saturated solution of aqueous sodium bicarbonate and methylene chloride (150 mL). Dry the organic layer over sodium sulfate and concentrate *in vacuo*. Purify the crude product using radial chromatography eluting with 8% MeOH/ CH_2Cl_2 to give 137 mg (52%) of the free base of the title compound.

25

Prepare the hydrochloride salt by adding 0.8 mL of a 1N HCl in Et₂O solution: mass spectrum (ion spray) $m/z = 458$ (M-Cl).

Example 5

- 5 1-(2-{4-[2-(2,4-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine hydrochloride



- Combine trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (2.99 g, 5.70 mmol), 2,4-difluoro-benzeneboronic acid (2.70 g, 17.09 mmol), palladium(II)acetate (0.13 g, 0.57 mmol), tricyclohexylphosphine (240 mg, 0.85 mmol), cesium fluoride (7.79 g, 51.25 mmol) and acetonitrile (70 mL) and heat at 90°C. After 10 minutes, cool to ambient temperature, filter and remove solvent under vacuum. Dissolve in dichloromethane and wash with 1N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride, dry with magnesium sulfate, filter and remove solvent under vacuum. Chromatograph on silica gel with dichloromethane/methanol mixtures and add 1M hydrogen chloride in ether (10 mL) to give 3.0 g (100%) of the title compound: mass spectrum (ion spray) $m/z = 488$ (M-Cl).

Example 6

- 20 6-(2,4-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride


- Dissolve 1-(2-{4-[2-(3,4-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine hydrochloride (3.00 g, 5.70 mmol) in dichloromethane (90 mL) and cool in an ice bath. Add boron tribromide (1M in dichloromethane, 18.0 mL, 18.0 mmol) and stir for 2.5 hours. Add methanol (20 mL), warm to ambient temperature and remove solvent under vacuum. Dissolve in dichloromethane with a minimum of methanol and wash with saturated aqueous sodium bicarbonate and remove solvent under

vacuum. Crystallize with ethyl acetate/dichloromethane, filter solid to give the free base of the title compound. Dissolve the free base in dichloromethane/methanol, add 1M hydrogen chloride in ether (10 mL) and remove solvent under vacuum to give 2.68 g (92%) of the title compound: mass spectrum (ion spray) $m/z=476$ (M-Cl).

5

Example 7

1-(2-(4-[2-(2,5-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy)-ethyl)-piperidine hydrochloride



10

Combine trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (154 mg, 0.29 mmol), 2,5-difluorophenyl boronic acid (139 mg, 0.88 mmol), [1,1'-bis(diphenylphosphino)-ferrocene]dichloropalladium (II), complex with dichloromethane (1:1) (239 mg, 0.29 mmol), cesium fluoride (400 mg, 2.63 mmol) and acetonitrile (6 mL), stir and heat at 90°C. After 4 hours, cool to ambient temperature and remove solvent under vacuum. Suspend and sonicate the residue in ethyl ether, filter and remove the solvent under vacuum. Chromatograph the crude mixture on silica gel with dichloromethane/methanol mixtures, combine fractions containing product, add 1M hydrogen chloride in ether (1 mL) and remove solvent under vacuum to give 140 mg of the title compound: mass spectrum (ion spray) $m/z=490$ (M-Cl).

20

Example 8

6-(2,5-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride


25

Dissolve 1-(2-(4-[2-(2,5-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy)-ethyl)-piperidine hydrochloride (133 mg, 0.25 mmol) in dichloromethane (5 mL), cool in an ice bath and add boron tribromide (1M in dichloromethane, 0.76 mL, 0.76 mmol). Let slowly warm to ambient temperature over 18 hours, quench with saturated

aqueous solution of sodium bicarbonate, dry organic layer with magnesium sulfate, filter and chromatograph on silica gel with dichloromethane/methanol mixtures. Combine fractions containing product, add 1M hydrogen chloride in ether (1 mL) and remove solvent under vacuum to give 108 mg (83%) of the title compound: mass spectrum (ion spray) $m/z=476$ (M-Cl).

Example 9


1-(2-{4-[6-Methoxy-2-(3,4,5-trifluoro-phenyl)-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine



Charge a flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (800 mg, 1.52 mmol), 3,4,5-trifluorobenzene boronic acid (804 mg, 4.57 mmol) and cesium fluoride (1.1 g, 7.6 mmol) and purge with nitrogen. In a separate flask, charge palladium(II)acetate (34 mg, 0.15 mmol) and tricyclohexylphosphine (64 mg, 0.23 mmol) and purge with nitrogen. Add degassed acetonitrile and sonicate under nitrogen for 10 minutes. Add the catalyst solution to the solids and plunge into an 80 °C oil bath for 10 minutes. Cool to room temperature and filter through celite. Concentrate and redissolve in methylene chloride. Wash with saturated aqueous sodium bicarbonate, separate, dry, filter and concentrate. Purify the residue over silica gel, eluting with 0 to 5% methanol in methylene chloride, to yield 720 mg (93%) of the title compound: mass spectrum (ion spray) 508.3 (M+H).

Example 106-(3,4,5-Trifluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol
hydrochloride

- 5 Dissolve 1-(2-{4-[6-methoxy-2-(3,4,5-trifluoro-phenyl)-naphthalen-1-yloxy]-
phenoxy}-ethyl)-piperidine (720 mg, 1.4 mmol) in methylene chloride (15 mL). Add 2M
HCl in ether (1.4 mL, 2.8 mmol) and concentrate *in vacuo*. Dissolve the residue in
methylene chloride (15 mL) and add boron tribromide (0.53 mL, 5.6 mmol) dropwise at 0
°C under nitrogen. Pour into cold saturated aqueous sodium bicarbonate after 45 minutes
10 and extract with methylene chloride. Concentrate the organic layer and purify the residue
over silica gel, eluting with 0 to 12% methanol in methylene chloride, to yield 554 mg
(80%) of the free base of the title compound. Dissolve the free base (554 mg, 1.1 mmol)
in ethyl acetate (6 mL) and ether (12 mL). Add 2M HCl in ether (1.1 mL, 2.2 mmol) and
collect the precipitate. Dry in a vacuum oven at 50 °C overnight to yield 467 mg (79%)
15 of the title compound: mass spectrum (ion spray) $m/z = 494.3$ (M-Cl).

Example 111-(2-{4-[2-(2,3-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-
piperidine

20

- Using the procedure demonstrated in Example 9, react trifluoromethanesulfonic
acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (800 mg,
1.52 mmol), 2,3-difluorobenzene boronic acid (720 mg, 4.57 mmol), cesium fluoride (2.1
25 g, 13.7 mmol), palladium(II)acetate (34 mg, 0.15 mmol) and tricyclohexylphosphine (64
mg, 0.23 mmol) to obtain 622 mg (84%) of the title compound: mass spectrum (ion
spray) 490.4 (M+H).


Example 12

6-(2,3-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol
hydrochloride

Using the procedure demonstrated in Example 10, react 1-(2-{4-[2-(2,3-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine (622 mg, 1.27 mmol), 2M HCl in ether (1.3 mL, 2.6 mmol) and boron tribromide (0.60 mL, 6.4 mmol) to give 309 mg (48%) of the title compound: mass spectrum (ion spray) 476.4 (M-Cl).

Example 13

10 1-(2-{4-[2-(3,5-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine



Using the procedure demonstrated in Example 9, react trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl ester (3.5 g, 6.67 mmol), 3,5-difluorobenzene boronic acid (3.1 g, 19.6 mmol), cesium fluoride (9.2 g, 60.4 mmol), palladium(II)acetate (145 mg, 0.64 mmol) and tricyclohexylphosphine (290 mg, 1.03 mmol) to obtain 3.3 g (100%) of the title compound: mass spectrum (ion spray) 490.3 (M+H).

20

Example 14


6-(3,5-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol
hydrochloride

25 Using the same procedure as for 6-(3,4,5-trifluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride salt; react 1-(2-{4-[2-(3,5-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine (3.8 g, 7.9 mmol), 2M HCl in ether (7.9 mL, 15.8 mmol) and boron tribromide (3.7 mL, 39.2 mmol) to give

2.6 g (64%) of the title compound after silica gel chromatography: mass spectrum (ion spray) 476.3 (M-Cl).

Example 15


5 6-(3,4-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride



10 Prepare 6-(3,4-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride in a manner similar to Examples 7 and 8 to provide 1.79 g of the title compound: mass spectrum (ion spray): $m/z=476$ (M-Cl).

Preparation 2

4-[2-(3-Fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenol



15

Charge an oven-dried 250 mL round-bottom flask with 6-methoxy-1-tetralone (3.0g, 17.0 mmol.) and place under nitrogen. Dissolve the solid in toluene (30mL) and add 1-bromo-3-fluorobenzene (4.7 mL, 42.6 mmol), sodium t-butoxide (6.5g, 68.1 mmol), palladium acetate (76mg, 0.34 mmol), and racemic BINAP (212mg, 0.34 mmol). Heat the solution to 115°C and stir for 18 hours. Dilute the solution with cold 5N HCl (50mL) and ethyl acetate (200mL). Separate the organic layer and dry over sodium sulfate, filter over a pad of celite and concentrate *in vacuo*. Purify the crude product using radial chromatography to give 3.4 g (74%) of the title compound. This material is used without further purification: mass spectrum (ion spray) $m/z=267$ (M-H).

20


25

Dissolve 2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-ol (3.36g, 12.5 mmol) in N-methyl-2-pyrrolidinone (NMP) (10mL) and add sodium hydride (500mg, 60% oil dispersion, 12.5 mmol) at room temperature. After stirring for 1 hour this solution is added to a solution of 4-fluorobenzaldehyde (2.4mL, 22.5 mmol) in NMP (10mL) that has been heated to 185°C. Continue stirring for 2.5 hours. Cool the reaction to room temperature and add pH 7 buffer (50mL) and extract with ethyl acetate (2 X 100mL). Wash the organic extracts with water and filter through a plug of silica gel. Purify the crude product using radial chromatography giving 2.50g (54%) of the title compound and use without further purification: mass spectrum (ion spray) $m/z = 371$ (M-H).

Charge a 100 mL round-bottom flask with 4-[2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-benzaldehyde (2.5g, 6.71 mmol) and ethyl acetate (5 mL). At room temperature add 2 mL of 35% hydrogen peroxide. To this solution slowly add 2 mL of concentrated sulfuric acid. The mixture warms to approximately 40 °C and returns to room temperature where it is stirred for 2 hours. Dilute the reaction with water and ethyl acetate (100 mL) and dry the organic layer over sodium sulfate, filter and concentrate *in vacuo*. Purify the crude product using radial chromatography eluting with CH_2Cl_2 to yield 540 mg (22%) of the title compound: mass spectrum (ion spray) $m/z = 359$ (M-H).

Example 16

1-(2-(4-[2-(3-Fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy)-ethyl)-piperidine hydrochloride



To 4-[2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenol (180 mg, 0.50 mmol) in 10mL anhydrous DMF is added sodium hydride (60 mg, 60% oil dispersion, 1.50 mmol) and the solution stirred 30 minutes at room temperature. Add 1-(2-chloroethyl)piperidine hydrochloride (138 mg, 0.75 mmol) and stir the reaction for 3 days. Dilute the reaction with methylene chloride, wash with saturated sodium bicarbonate (1x), brine (1x), extract the organics and dry over sodium sulfate. Purify the crude product

using radial chromatography eluting with 4% MeOH/CH₂Cl₂ to yield 234 mg (99%) of the free base of the title compound. Form the hydrochloride by adding 0.8 mL of a 1N HCl in Et₂O solution: mass spectrum (ion spray) m/z = 472 (M-Cl).

5

Example 17


6-(3-Fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol
hydrochloride

Charge a 100mL round-bottom flask with 1-(2-{4-[2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine hydrochloride (245mg, 0.48mmol) and cooled to 0 °C under nitrogen. Add 1.45mL of a 1M CH₂Cl₂ solution of BBr₃ and monitor the reaction by ES-MS. After stirring for 1 hour, pour the reaction into a cold saturated solution of aqueous sodium bicarbonate and methylene chloride (150mL). Dry the organic layer over sodium sulfate and concentrate *in vacuo*. Purify the crude product using radial chromatography eluting with 4% MeOH/CH₂ to give 139 mg (63%) of the free base of the title compound. Form the hydrochloride salt by adding 0.8 mL of a 1N HCl in Et₂O solution: mass spectrum (ion spray) m/z = 458(M-Cl).

20

Preparation 3

4-[6-Benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-phenol



25

Add bromine (107 mL, 2.08 mol) into a solution of 6-benzyloxy-3,4-dihydro-2H-naphthalen-1-one (250 g, 0.99 mol) in chloroform (2 L) at 5 °C over 1.5 hours. Add sodium thiosulfate solution (250 mL) to quench the reaction at 0 °C. Add ethyl acetate (1 L) and separate layers. Extract the aqueous layer with CH₂Cl₂ (500 mL) and combine the organic layers, wash with aqueous sodium bicarbonate solution and brine. Dry with sodium sulfate and concentrate *in vacuo*. Triturate the residue by adding 10% ethyl

acetate in hexane (600 mL) to obtain a solid. Filter and dry the solid to get 405 g (100 %) of 6-benzyloxy-2,2-dibromo-3,4-dihydro-2H-naphthalen-1-one.

Add 1M sodium methoxide (215 mL, 0.99 mol) into a solution of 6-benzyloxy-2,2-dibromo-3,4-dihydro-2H-naphthalen-1-one (205 g, 0.5 mol) in methanol (1.3 L). Heat
5 the suspension to dissolution. Cool the reaction mixture to 0 °C and add 1N HCl (540 mL). Add H₂O (3 L) and cool to 3 °C to obtain a solid. Filter and dry the solid to obtain 152 g (92 %) of 6-benzyloxy-2-bromo-naphthalen-1-ol.

Add sodium hydride (24 g, 0.6 mmol) portionwise to a solution of 6-benzyloxy-2-bromo-naphthalen-1-ol (179 g, 0.54 mol) in THF (3.0 L) at 0 °C. Add
10 methanesulfonyl chloride (47 mL, 0.61 mol) over 45 minutes and stir the reaction for 1.5 hours at 10 °C. Add sodium bicarbonate solution (500 mL) and water (500 mL). Separate the layers and extract the aqueous layer with ethyl acetate (500 mL x2). Combine the organic layers and wash with brine (200 mL). Dry with magnesium sulfate, filter and concentrate *in vacuo*. Triturate the residue by adding 20% ethyl acetate in hexane (1 L) to
15 obtain a solid. Filter, wash the solid with toluene (200 mL x 2) and dry the solid to get 176 g (80 %) of methanesulfonic acid 6-benzyloxy-2-bromo-naphthalen-1-yl ester.

Combine methanesulfonic acid 6-benzyloxy-2-bromo-naphthalen-1-yl ester (10.0 g, 24.4 mmol), 4-fluorophenylboronic acid (10.2 g, 72.9 mmol), sodium carbonate (7.8 g, 73.6 mmol) and tetrakis(triphenylphosphine) palladium (2.8 g, 2.4 mmol) in a mixture of
20 toluene (300 mL), ethanol (60 mL) and water (40 mL). Heat the mixture at 100 °C for 12 hours. Cool and filter the suspension through a pad of celite. Evaporate the solvent *in vacuo*. Wash the residue with sodium bicarbonate solution and brine. Dry with magnesium sulfate and concentrate *in vacuo*. Purify the residue over silica gel, eluting the material with a step gradient of methanol/dichloromethane (0 to 10%), to obtain 10.1 g
25 (98%) of methanesulfonic acid 6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yl ester.

Dissolve methanesulfonic acid 6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yl ester (5.2 g, 12.3 mmol) in 5M sodium hydroxide (12 mL, 60 mmol), THF (86 mL) and MeOH (86 mL). Heat to 50 °C for 1 hour. Cool and add ethyl acetate (100 mL). Wash
30 the organic layer with 1N HCl, saturated sodium bicarbonate solution and brine. Dry with magnesium sulfate and concentrate *in vacuo* to obtain 3.4 g (89%) of 6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-ol.


Add sodium hydride (400 mg, 10 mmol) into a solution of 6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-ol in NMP (40 mL). Add the above alkoxide suspension into a solution of 4-fluorobenzaldehyde (2 mL, 19 mmol) in NMP (30 mL) at 165 °C. Heat at 165 °C for 1 hour. Cool and add buffer solution (pH=7, 10 mL). Add diethyl ether (1 L).

- 5 Separate the layers and wash the aqueous layer with diethyl ether (2 x 200 mL). Combine the organic layers, dry with magnesium sulfate and concentrate *in vacuo*. Chromatograph the residue on a biotage column eluting the material with a step gradient of methanol/dichloromethane (0 to 10%) to obtain 2.9 g (70%) of 4-[6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-benzaldehyde.

- 10 Add 18M H₂SO₄ (1 mL, 16.8 mmol) dropwise into a solution of H₂O₂ (1 mL, 9.7 mmol) and 4-[6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-benzaldehyde at 0 °C and stir at room temperature for 12 hours. Add H₂O (20 mL) and CH₂Cl₂ (100 mL). Separate layers and extract the aqueous layer with CH₂Cl₂ (2 x 50 mL). Combine the organic layers, dry with magnesium sulfate and concentrate *in vacuo* to obtain 1.88 g
15 (73%) of the title compound: mass spectrum (ion spray) m/z=435.1 (M-H).

Example 18

1-(2-{4-[6-Benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine



20

- Dissolve 4-[6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-phenol (5.20 g, 11.91 mmol) in DMF (60 mL) under N₂ and add NaH (1.43 g, 35.74 mmol, 60%wt). Stir the solution for 0.5 hours at room temperature then add 1-(2-chloro-ethyl)-piperidine, HCl salt (3.29 g, 17.87 mmol). Continue to stir the solution for and then add water (300 mL).
25 Extract the aqueous layer with CH₂Cl₂ (3 x 300 mL) and then combine the organic layers. Dry the organic layer with Na₂SO₄, then filter, concentrate and purify it by flash column

chromatography (silica gel, 0-4% MeOH-NH₄OH (10/1, v/v)/CH₂Cl₂) to give 6.5 g (99%) of the title compound: mass spectrum (ion spray) $m/z = 548.3$ (M+H).


Example 19

5 6-(4-Fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride

Dissolve 1-(2-{4-[6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine (6.5 g, 11.87 mmol) in MeOH/THF (200 mL, v/v=1/1) under N₂. Add Pd/C (0.65 g, 10%) and exchange the N₂ for H₂ three times. Stir the reaction mixture for two hours then filter out the Pd/C. Remove the solvent and purify the residue by column chromatography (silica gel, 2-8% MeOH-NH₄OH (10/1, v/v)/CH₂Cl₂) to give 2.93 g (54%) of the free base of the title compound. Dissolve the free base (2.93 g, 6.41 mmol) in CH₂Cl₂ (100 mL), and cool it to -78 °C. Add HCl (10 mL, 2.0 M in Et₂O), and stir the solution for 10 minutes. Remove the solvent under reduced pressure and at 40 °C, overnight, *in vacuo* to give 3.17 g (100%) of the title compound: mass spectrum (ion spray) $m/z = 458.2$ (M-Cl).

Preparation 4

20 Trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-phenoxy]-6-methoxy-naphthalen-2-yl ester



Add sodium hydride (18 g, 0.45 mol) into a solution of 4-benzyloxyphenol (41 g, 0.20 mol) and 2-(hexamethyleneimino)ethyl chloride hydrochloride (44 g, 0.22 mmol) in THF (600 mL) and DMF (100 mL) at room temperature. Heat to 60°C for 30 minutes. Pour the solution into ice and water. Dilute with ethyl acetate (500 mL) and separate layers. Dry the organic layer with magnesium sulfate, filter and concentrate under reduced

pressure to give brown oil. Dissolve the oil in ethyl acetate (500 mL) and methanol (500 mL). Add ammonium formate (100 g, 1.59 mol) and palladium on carbon (10 g, 9.4 mmol). Heat the mixture to reflux for 30 minutes. Add ammonium formate (100 g, 1.59 mol) and palladium on carbon (10 g, 9.4 mmol). Heat the reaction mixture for 30 minutes. Filter the suspension through a pad of celite and elute with ethyl acetate (500 mL). Evaporate solvent under reduced pressure and add water (100 mL). Dilute the mixture with ethyl acetate (500 mL) and separate layers. Wash the organic layer with saturated sodium bicarbonate solution (2 x 200 mL), dry with magnesium sulfate, filter and evaporate solvent under reduced pressure to give 31 g (64 %) of 4-(2-azepan-1-yl-ethoxy)-phenol.

Combine 2-benzyloxy-1-bromo-6-methoxy-naphthalene (31 g, 90 mmol), 4-(2-azepan-1-yl-ethoxy)-phenol (31 g, 132 mmol), copper bronze (12 g, 189 mmol), potassium carbonate (25 g, 181 mmol) and pyridine (400 mL). Heat the reaction mixture to reflux for 85 hours. Cool and filter the residue with celite and elute with methanol and methylene chloride (500 mL, V/V = 1:5). Evaporate solvent under reduced pressure and chromatograph the residue on a silica gel column eluting the material with a step gradient of methanol/dichloromethane (0 to 10%) to get 19 g (43%) of 1-{2-[4-(2-benzyloxy-6-methoxy-naphthalen-1-yloxy)-phenoxy]-ethyl}-azepane.


Dissolve 1-{2-[4-(2-benzyloxy-6-methoxy-naphthalen-1-yloxy)-phenoxy]-ethyl}-azepane (19 g, 38 mmol) in ethyl acetate (500 mL) and methanol (600 mL). Heat the mixture to obtain a clear solution. Cool to room temperature. Add ammonium formate (30 g, 476 mmol) and palladium on carbon (2 g, 1.9 mmol). Heat to reflux for 30 minutes. Add ammonium formate (7 g, 111 mmol) and palladium on carbon (0.7 g, 0.7 mmol). Heat to reflux for 30 minutes. Filter the suspension through a pad of celite and elute with ethyl acetate (500 mL). Evaporate solvent under reduced pressure and add water (100 mL). Dilute the mixture with ethyl acetate (500 mL) and separate layers. Wash the organic layer with saturated sodium bicarbonate solution (2 x 200 mL), dry with magnesium sulfate, filter and evaporate solvent under reduced pressure to give 15.1 g (97%) of 1-[4-(2-azepan-1-yl-ethoxy)-phenoxy]-6-methoxy-naphthalen-2-ol.

Add trifluoromethanesulfonic anhydride (7 mL, 42 mmol) into a solution of 1-[4-(2-azepan-1-yl-ethoxy)-phenoxy]-6-methoxy-naphthalen-2-ol (15 g, 37 mmol), triethylamine (20 mL) and methylene chloride (500 mL) at -50°C. Warm the reaction

mixture to room temperature and stir for 1 hour at that temperature. Cool the reaction mixture to -78°C and add brine (20 mL). Warm the reaction to room temperature. Separate layer and wash the organic layer with saturated sodium bicarbonate solution (100 mL) and brine. Dry the organic layer with magnesium sulfate, filter and evaporate solvent under reduced pressure. Chromatograph the residue on a silica gel column eluting the material with a step gradient of methanol/dichloromethane (0 to 10%) to get 20 g (99%) of trifluoro-methanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-phenoxy]-6-methoxy-naphthalen-2-yl ester.

Example 20

1-(2-{4-[2-(3,5-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-azepane




Dissolve trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-phenoxy]-6-methoxy-naphthalen-2-yl ester (435 mg, 0.80 mmol), cesium fluoride (864 mg, 5.7 mmol) and 1,3-difluoro-benzene boronic acid (383 mg, 2.4 mmol) in dry acetonitrile (5 mL) and stir for 10 minutes. In a separate flask suspend palladium acetate (18 mg, 0.08 mmol), and tricyclohexyl phosphine (33 mg, 0.12 mmol) in dry acetonitrile (15 mL) and sonicate under nitrogen for 10 minutes. Combine contents of both flasks and heat reaction at 60°C for 15 minutes. Cool reaction and filter through celite and concentrate *in vacuo*. Purify crude product by silica gel chromatography using a 1-3% gradient of methanol in dichloromethane to yield 400 mg (98%) of the title compound: mass spectrum (ion spray) $m/z = 504.2$ (M+H).

Example 215-[4-(2-Azepan-1-yl-ethoxy)-phenoxy]-6-(3,5-difluoro-phenyl)-naphthalen-2-ol
hydrochloride

- 5 Dissolve 1-(2-{4-[2-(3,5-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-
phenoxy}-ethyl)-azepane (583 mg, 1.2 mmol) in dichloromethane (10 mL). Cool to 0 °C,
add 2M HCl(1.2 mL, 2.3 mmol) and stir at room temperature for 15 minutes. Concentrate
in vacuo. Redissolve the salt in dichloromethane (10 mL) and cool to 0 °C. Add boron
tribromide (972 mg, 3.5 mmol) dropwise and bring to room temperature. Stir reaction for
10 1.5 hours and pour reaction mixture onto ice, saturated sodium bicarbonate (10 mL) and
methanol (10 mL). Extract with dichloromethane, combine extracts and wash with water
and saturated sodium bicarbonate. Dry with sodium sulfate, filter, and concentrate *in*
vacuo. Purify by silica gel chromatography using a 1-4% gradient of methanol in
dichloromethane to yield 366 mg (65%) of the free base of the title compound. Dissolve
15 free-base in 10 mL dichloromethane and add 2M HCl (0.8 mL) stir for 10 minutes and
concentrate *in vacuo* to yield 343 mg (88%) of title compound: mass spectrum (ion spray)
 $m/z = 490.3$ (M-Cl).

Example 22

- 20 1-(2-{4-[2-(3,4-Difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-
azepane



- Combine palladium acetate (33 mg, 0.15 mmol), tricyclohexyl phosphine (61 mg,
25 0.22 mmol) and acetonitrile (6 mL). Sonicate the mixture for 5 minutes. Combine
trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-phenoxy]-6-methoxy-
naphthalen-2-yl ester (787 mg, 1.46 mmol), cesium fluoride (2.00 g, 13.2 mmol), 3,4-
difluorophenylboronic acid (692 mg, 4.38 mmol) and acetonitrile (16 mL). Add the
sonicated Pd/Pcy₃ suspension to reaction vessel and heat to 90 °C for 30 minutes. Cool to

room temperature and filter through pad of Celite and evaporate the solvent. Dissolve residue in ethyl acetate (40 mL) and wash with saturated NaHCO₃ (10 mL). Separate the layers, wash the organic layer with brine (10 ml), dry with MgSO₄, filter, and concentrate *in vacuo*. Chromatograph the residue on a SiO₂ column eluting the material with
5 methanol in dichloromethane (0 to 5%) to give 630 mg (86 %) of the title compound: mass spectrum (ion spray) $m/z = 504.2$ (M+H).


Example 23

10 5-[4-(2-Azepan-1-yl-ethoxy)-phenoxy]-6-(3,4-difluoro-phenyl)-naphthalen-2-ol hydrochloride.

Dissolve 1-(2-{4-[2-(3,4-difluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-azepane (630 mg, 1.25 mmol) in dichloromethane (20 ml). Add 2M HCl in diethyl ether (1 mL, 2.0 mmol). Stir for 5 minutes. Concentrate the slurry and dry *in vacuo*. Dilute the residue in dichloromethane (20 ml) and blanket with nitrogen. Cool the
15 solution to 0 °C with external ice bath. Add BBr₃ (0.4 mL, 4.3 mmol). Stir the reaction at room temperature for 30 minutes and add the reaction mixture in saturated aqueous NaHCO₃ (20 ml), ice (5 g) and methanol (5 mL). Dilute with dichloromethane (20 mL), separate the layers, wash the organic layer with brine (10 ml), dry with MgSO₄, filter, and
20 concentrate *in vacuo*. Chromatograph the residue on a SiO₂ column eluting the material with a step gradient of methanol/dichloromethane (0 to 5%) to get the free base of the title compound. Dissolve the free base in diethyl ether (5.0 ml), ethyl acetate (6.0 ml) and methanol (1.0 ml) and add 2M HCl (1 mL, 2.0 mmol) in diethyl ether. Collect the precipitate on filter paper, rinse with diethyl ether and dry *in vacuo* (<2mm of Hg) to give
25 310 mg (47 %) of the title compound: mass spectrum (ion spray) $m/z = 490.3$ (M-Cl).

Example 24

1-(2-{4-[2-(3-Fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-azepane
hydrochloride



5

Prepare this compound following the procedure to make 1-(2-{4-[2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine above, using 2-(hexamethyleimino)-ethyl chloride hydrochloride to get a 100% yield of the free base of the title compound after radial chromatography. Form the hydrochloride salt by adding
0.8 mL of a 1 M HCl in Et₂O solution: mass spectrum (ion spray) m/z =486 (M-Cl).

10

Example 25

5-[4-(2-Azepan-1-yl-ethoxy)-phenoxy]-6-(3-fluoro-phenyl)-naphthalen-2-ol
hydrochloride


15

Prepare this compound following the procedure to make 6-(3-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol hydrochloride above starting with 1-(2-{4-[2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-azepane hydrochloride, to get a 52% yield of the free of the title compound after radial chromatography. Form the hydrochloride salt by adding 0.8mL of a 1 M HCl in Et₂O solution: mass spectrum (ion spray) m/z =472 (M-Cl).

20

Example 26

1-(2-{4-[6-Benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-phenoxy}-ethyl)-azepane



25

Add sodium hydride (324 mg, 8.0 mmol) into a solution of 4-[6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-phenol (1.18 g, 2.7 mmol) in DMF (10 mL) and stir for 20 minutes at room temperature. Add 2-(hexamethylenimine)ethyl chloride
5 hydrogen chloride (1.07 g, 5.4 mmol) and stir at room temperature for 12 hours. Add H₂O (10 mL) and diethyl ether (100 mL). Separate layers and wash the aqueous layer with diethyl ether (2 x 50 mL). Combine organic layers, dry with magnesium sulfate and concentrate *in vacuo*. Purify the residue over silica gel, eluting the material with a step
10 gradient of methanol/dichloromethane (0% to 10%), to obtain 1.0 g of the title compound (66%): mass spectrum (ion spray) $m/z=562.3$ (M+H).

Example 27

5-[4-(2-Azepan-1-yl-ethoxy)-phenoxy]-6-(4-fluoro-phenyl)-naphthalen-2-ol
hydrochloride


15

Add ammonium formate (614 mg, 9.7 mmol) and palladium on carbon (10 mol%) into a solution of 1-(2-{4-[6-benzyloxy-2-(4-fluoro-phenyl)-naphthalen-1-yloxy]-
phenoxy}-ethyl)-azepane (709 mg, 1.26 mmol) in MeOH (20 mL) and ethyl acetate (12
mL). Heat to reflux for 1 hour. Cool and filter the suspension through a pad of celite.
20 Evaporate the solvent, dilute with CH₂Cl₂ and wash with H₂O (20 mL). Dry the organic layer with magnesium sulfate and concentrate *in vacuo* to obtain the free base of the title compound. Dissolve the free base in ethyl acetate (2 mL), diethyl ether (2 mL) and MeOH (0.1 mL). Add 2M HCl (1 mL, 20 mmol), concentrate the slurry and dry *in vacuo*
to give the title compound (270 mg, 50% yield): mass spectrum (ion spray) 472.3(M-Cl).

25

Preparation 5

Trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-
naphthalen-2-yl ester



In a dry round bottom flask equipped with stir bar, temperature probe and N₂ line, dissolve 2,6-dimethoxynaphthalene (1.0 eq) in CH₂Cl₂ (5 volume equivalents) at ambient temperature. Cool the solution to 0 °C in with an ice bath, and add 4-(2-piperidin-1-yl-ethoxy)-benzoyl chloride (1.1 eq). Add aluminum chloride (2.0 eq). Once the reaction is determined to be complete, quench the reaction slowly with 1 N NaOH and dilute with additional water and CH₂Cl₂. Wash the aqueous layer with (1 x 20 mL) of CH₂Cl₂. Combine the organic extracts and wash with brine and dry (Na₂SO₄). Recrystallize the crude product from methanol to give (2,6-dimethoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (average yield 68%).


Dissolve (2,6-dimethoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone in CH₂Cl₂ (10 volume equivalents) in a 3-neck round bottom flask equipped with a pressure equalizing addition funnel, stirbar, and N₂ source. Cool the flask in an ice/brine bath and add 1.0 M BCl₃ solution in CH₂Cl₂ (1.2 equivalents) dropwise. The reaction solution turns dark red and the temperature initially increases to 5 °C. Within one hour, all starting material is consumed, as determined by TLC (1:1, Ether:Petroleum Ether). Quench the reaction with methanol (5 equivalents) and allow to warm to room temperature. Dilute the organic solution with CH₂Cl₂ (one volume equivalent) and add to a 1.0 M NaHCO₃ solution (5 volume equivalents) and stir for one hour. Separate the aqueous and organic layers. Wash the aqueous layer with CH₂Cl₂ (one volume) and the combine organic layers, wash with saturated NH₄Cl and dry over Na₂SO₄. Purify the product via column chromatography (50/1 silica gel) eluting with CH₂Cl₂/Hexanes (3/1) to yield (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (typical yield 87 %).

Dissolve (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone in CH₂Cl₂ (10 volumes) in a three neck round bottom flask equipped with a stir bar and N₂ source and chill to 0°C in an ice/brine bath. Add pyridine (1.3 equivalents). Add trifluoromethane sulfonyl chloride (1.2 equivalents) via syringe over 15 minutes. After 15 minutes, quench the reaction with H₂O (10 volumes), wash with 1 N HCl (5 volumes), wash with 1.0 N NaHCO₃, and dry over Na₂SO₄. Concentrate to

give the title compound in quantitative yield. Use the product without further purification.

Example 28

5 [2-(2,4-Difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (12.4 g, 23.0 mmol) and 2,4-difluorophenylboronic acid (7.0 g, 46.0 mmol) in degassed dimethoxyethane (620 mL). Add 2M aqueous sodium carbonate (73 mL, 145 mmol) and stir at room temperature under nitrogen for 5 minutes. Add palladium(II) acetate (520 mg, 2.3 mmol) and triphenylphosphine (1.2 g, 4.6 mmol) and plunge into a 85 °C oil bath. Stir for 40 minutes and cool to room temperature. Pour into saturated aqueous sodium bicarbonate and extract twice with methylene chloride. Dry the combined organic layers with sodium sulfate, filter and concentrate *in vacuo*. Purify the resultant oil with SCX columns (load in methanol, elute with 2M NH₃/MeOH) to yield 10.8 g (93%) of the title compound: mass spectrum (ion spray) *m/z* = 502.3 (M+H).

20

Example 29


[2-(2,4-Difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride

25 Dissolve [2-(2,4-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (10.8 g, 21.5 mmol) in methylene chloride (200 mL). Add 2M HCl in ether (21.5 mL, 43 mmol) and concentrate *in vacuo*. Redissolve the foam in methylene chloride (200 mL) and cool to 0 °C under nitrogen. Slowly add boron

tribromide (10.1 mL, 107 mmol) and stir at 0 °C for 30 minutes. Slowly pour into saturated aqueous sodium bicarbonate and extract with 20% IPA in chloroform. Dry the organic layer with sodium sulfate, filter and concentrate *in vacuo* to yield 10.5 g (100%) of the free base of the title compound: ¹H-NMR (CDCl₃) δ 7.72 (d, *J* = 8.6 Hz, 1H), 7.49 (d, *J* = 8.6 Hz, 3H), 7.35 (d, *J* = 8.4 Hz, 1H), 7.18 (t, *J* = 7.8 Hz, 1H), 7.14 (d, *J* = 1.9 Hz, 1H), 6.96 (dd, *J* = 9.2, 2.3 Hz, 1H), 6.74-6.62 (m, 2H), 6.58 (d, *J* = 8.6 Hz, 2H), 4.08 (t, *J* = 5.9 Hz, 2H), 2.79 (t, *J* = 5.6 Hz, 2H), 2.55 (bs, 4H), 1.63 (bs, 4H), 1.45 (m, 2H). Dissolve the free base in a 1 : 1 mixture of acetonitrile : water. Add an appropriate amount of 5 M hydrochloric acid and lyophilize the mixture to afford the title compound.

Example 30

[2-(2,5-Difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (4.51 g, 8.4 mmol) in acetonitrile (140 mL). Add Pd(OAc)₂ (0.28 g, 1.3 mmol), tricyclohexylphosphine (0.59 g, 2.1 mmol), cesium fluoride (11.4 g, 75.6 mmol) and 2,5-difluorobenzeneboronic acid (2.56 g, 16.2 mmol). Flush the flask with nitrogen then heat the reaction mixture to 90 °C. Heat the reaction mixture for one hour and then cool it to room temperature. Add water (400 mL) and extract the aqueous layer with methylene chloride (3 × 400 mL). Combine the organic layers and dry with sodium sulfate, filter, concentrate and purify by flash column chromatography (0-4% MeOH-NH₄OH (10/1, v/v)/ CH₂Cl₂) to give 2.42 g (68%) of the title compound: mass spectrum (ion spray) *m/z* = 502.3 (M+H).


Example 31

[2-(2,5-Difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride

5 Demethylate [2-(2,5-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (2.42 g, 4.82 mmol) with BBr_3 in a procedure similar to the preparation of 2-(2,4-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone to give 1.96 g (83%) of the free base of the title compound: mass spectrum (ion spray) $m/z = 488.3$ ($\text{M}+\text{H}$). Dissolve the free base in
10 a 1 : 1 mixture of acetonitrile : water. Add an appropriate amount of 5 M hydrochloric acid and lyophilize the mixture to afford the title compound.

Example 32


Methanesulfonic acid 6-(2,4-difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-
15 naphthalen-2-yl ester



Dissolve [2-(2,4-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (540 mg, 1.11 mmoles), and methane sulfonyl chloride
20 (254 mg, 2.22 mmoles) in 10 ml acetonitrile and add triethylamine (224 mg, 2.22 mmoles). Stir the mixture for 5 days at room temp. Add equivalent amounts of the sulfonyl chloride and triethylamine and stir for 30 minutes. Evaporate the mixture to dryness, dissolve in methanol and pass through an SCX column. Wash the column with methanol and elute the product with 2 N ammonia/methanol to yield 433 mg (69%) of the
25 title compound: mass spectrum (ion spray) $m/z = 566$ ($\text{M}+\text{H}$).

Example 33

[2-(2,6-Difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



5

Charge a flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (2.0 g, 3.7 mmol), 2,6-difluorophenyl boronic acid (1.17 g, 7.4 mmol), tetrakis(triphenylphosphine)palladium (0) (855 mg, 0.74 mmol) and potassium phosphate (4.7 g, 22.2 mmol) add 100 mL of dry DMF and heat under nitrogen at 100 °C for two hours. Cool the reaction and filter. Purify on an SCX column eluting with 2N ammonia/methanol. Purify further on a silica gel column eluting with a gradient of 0-10% methanol/methylene chloride. The yield is 1.5 g (81%): ¹H-NMR (CDCl₃, 400 MHz) δ 7.90 (d, J = 8.4 Hz, 1H); 7.63 (d, J = 8.4 Hz, 1H); 7.62 (d, J = 9.2 Hz, 2H); 7.39 (d, J = 8.4 Hz, 1H); 7.23 (d, J = 2.8 Hz, 1H); 7.18-7.08 (m, 2H); 6.78 (d, J = 10.4 Hz, 2H); 6.74 (s, 2H); 4.11-4.08 (m, 2H); 3.95 (s, 3H); 2.75 (t, J = 6.4 Hz, 2H); 2.49-2.49 (m, 4H); 1.63-1.58 (m, 4H); 1.47-1.44 (m, 2H).

15

Example 34

[2-(2,6-Difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone

20

Dissolve [2-(2,6-difluorophenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-ylethoxy)-phenyl]-methanone (1.5 gm., 3.0 mmoles) in 500 ml methylene chloride and chill in ice. To this solution add boron tribromide (6.0 ml, 63 mmoles) in portions with swirling between additions. Allow to come to room temp. and stir for one hour. Pour into a two-phase system consisting of an organic layer of 3/1 chloroform/isopropanol and an aqueous layer of saturated sodium bicarbonate. Separate the phases and dry the organic layer using 3A molecular sieves. Purify on a silica column eluting with a 0-10%


25

methanol/methylene chloride gradient. The yield of pure product is 600 mg (44%): ¹H-NMR (CD₃OD, 400 MHz) δ 7.87 (d, J = 8.0 Hz, 1H); 7.56 (d, J = 8.4 Hz, 2H); 7.49 (d, J = 9.2 Hz, 1H); 7.33 (d, J = 8.8 Hz, 1H); 7.27-7.25 (m, 1H); 7.23-7.21 (m, 1H); 7.06 (dd, J = 8.8, 2.4 Hz, 1H); 6.86-6.79 (m, 4H); 4.14 (t, J = 5.6 Hz, 2H); 2.76 (t, J = 5.6 Hz, 2H);

5 2.53-2.53 (m, 4H); 1.65-1.59 (m, 4H); 1.50-1.46 (m, 2H).

Preparation 6

Trifluoromethanesulfonic acid 6-benzyloxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester



10


Dissolve trifluoromethanesulfonic acid 6-hydroxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (9.00 g, 17.2 mmol) in THF (540 mL). Stir the solution at 0 °C under N₂ and add benzyl alcohol (2.78 g, 25.8 mmol), polymer-PPh₃ (8.60 g, 25.8 mmol) and DIAD (5.21 g, 25.8 mmol). Continue to stir the reaction mixture at room

15 temperature for 2 hours. Add water (1000 mL), and extract the aqueous layer with CH₂Cl₂ (3 × 500 mL). Combine the organic layers and dry with Na₂SO₄, filter, concentrate and purify by flash chromatography (silica gel, 0-4% MeOH-NH₄OH (10/1, v/v)/CH₂Cl₂) to give 10.0 g (96%) of the title compound: mass spectrum (ion spray) m/z =

20 614.1 (M+H).

Example 35

[6-Benzyloxy-2-(2-fluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



5.

Dissolve trifluoromethanesulfonic acid 6-benzyloxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (1.00g, 1.63 mmol) in 20 ml of acetonitrile and add 2-fluorobenzene boronic acid (0.46 g, 3.26 mmol),

trans[dichlorobis(triphenylphosphine)] palladium II (0.23 gm., 0.33 mmol) and sonicate briefly. Next add cesium fluoride (2.23 g, 14.67 mmol) and heat to 75 °C for one hour. Add Celite and filter. Concentrate the solvent under vacuum, dissolve in methanol and purify on an SCX cartridge, eluting with 2N ammonia/methanol. Further purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to isolate 550 mg of the title compound (60%).

15

Example 36

[2-(2-Fluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride


20

Dissolve [6-benzyloxy-2-(2-fluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (0.55 g, 0.98 mmol) in 25 ml of ethanol and after a nitrogen purge add 10% palladium on carbon (60 mg) and hydrogen (1 atm). After 12 hours, filter over celite and concentrate the solvent under vacuum, purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to isolate 350 mg of the title compound (76%). Convert to the hydrochloride salt to give the title compound.

25

Example 37

[6-Methoxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



5

Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (752 mg, 1.4 mmol), 2,4,6-trifluorophenylboronic acid (493 mg, 2.8 mmol), potassium phosphite (1.8 g, 8.4 mmol) and tetrakis(triphenylphosphine)palladium (324 mg, 0.3 mmol) in dry DMF (25 mL) and heat at 100 °C for 20 minutes. Purify reaction on an SCX column to yield 674 mg (93%) of the title compound: mass spectrum (ion spray) $m/z = 520.2$ (M+H).

10

Example 38

[6-Hydroxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone

15


Dissolve [6-methoxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (670 mg, 1.3 mmol) in dichloromethane (10 mL). Cool to 0 °C, add 2M HCl (1.3 mL, 2.6 mmol) and stir at room temperature for 15 minutes. Concentrate *in vacuo*. Redissolve the salt in dichloromethane (10 mL) and cool to 0 °C. Add boron tribromide (1.1 g, 3.9 mmol) dropwise and bring to room temperature. Stir reaction for 1.5 hours and pour reaction mixture onto ice, saturated sodium bicarbonate (10 mL) and methanol (10 mL). Extract with dichloromethane, combine extracts and wash with water and saturated sodium bicarbonate. Dry with sodium sulfate, filter, and concentrate *in vacuo*. Purify by silica gel chromatography using a 1-3% gradient of methanol in dichloromethane to yield 454 mg (70%) of the title compound: mass spectrum (ion spray) $m/z = 506.3$ (M+H).

20

25

Preparation 7


Trifluoromethanesulfonic acid 6-methanesulfonyloxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester



5 Suspend trifluoromethanesulfonic acid 6-hydroxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (12.5 g, 24 mmol) in dry methylene chloride (100 ml). Add diisopropylethylamine (8.3 mL, 48 mmol). Slowly add methanesulfonyl chloride (2.7 mL, 36 mmol). Pour reaction into saturated aqueous sodium bicarbonate after 20 minutes and extract with methylene chloride. Wash the organic layer with water, dry with
10 sodium sulfate, filter and concentrate *in vacuo* to yield 14.2 g (99%) of the title compound.

Example 39

15 [6-Hydroxy-2-(2,3,5-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone




20 Dissolve trifluoromethanesulfonic acid 6-methanesulfonyloxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (7.0 g, 11.6 mmol) in degassed acetonitrile (100 mL). Add cesium fluoride (9.1 g, 58 mmol) and bis(acetato)bis(triphenylphosphine)palladium (0.87 g, 1.2 mmol) followed by bis(neopentyl glycolato)diboron (3.1g, 13.9 mmol) and plunge into a 75 °C oil bath under nitrogen. After 15 minutes, add 1-bromo-2,3,5-trifluorobenzene (4.9 g, 23.2 mmol) to the reaction and bis(acetato)bis(triphenylphosphine)palladium (200 mg) and stir at 75 °C for
25 2.5 hours. Cool the reaction to room temperature and filter through celite. Concentrate

the filtrate *in vacuo* and redissolve the residue in methanol (100 mL). Add KOH (5g) and stir at room temperature overnight. Pour the reaction into saturated aqueous ammonium chloride and extract with methylene chloride. Dry the organic layer with sodium sulfate, filter and concentrate *in vacuo*. Purify on silica gel (0% to 6% methanol in methylene chloride) to obtain 3.7 g (64%) of the title compound: mass spectrum (ion spray) $m/z = 506.3$ (M+H).

Example 40

[6-Methoxy-2-(2,3,6-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



Couple trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (1.81 g, 3.37 mmol) with 2-bromo-1,3,4-trifluoro-benzene (1.42 g, 6.75 mmol) in a procedure similar to the preparation of 6-hydroxy-2-(2,3,5-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone to give 0.79 g (45%) of the title compound: mass spectrum (ion spray) $m/z = 520.3$ (M+H).


Example 41

[6-Hydroxy-2-(2,3,6-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone

Demethylate [6-methoxy-2-(2,3,6-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (0.79 g, 1.52 mmol) with BBR_3 in a procedure similar to the preparation of 2-(2,4-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone to give 0.67 g (88%) of the title compound: mass spectrum (ion spray) $m/z = 506.3$ (M+H).

Example 42

[6-Methoxy-2-(2,3,4-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



5

Charge a flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (2.13 g, 4.0 mmol), 2,3,4-trifluorophenyl boronic acid (1.0 g, 5.7 mmol), trans-dichlorobis(triphenylphosphine)palladium II, (561 mg, 0.8 mmol) and cesium fluoride (5.5 g, 36 mmol) and add 50 mL of acetonitrile. Heat the mixture at 80 °C for 4 hours. Cool and filter the mixture and purify on an SCX column, eluting with 2N ammonia/methanol. Purify further on a silica column eluting with 2% 2N ammonia/methanol/methylene chloride to give 880 mg (43%) of the title compound: ¹H-NMR (CD₃OD, 400 MHz) δ 7.93 (d, J=8.8Hz, 1H); 7.50 (d, J = 8.4 Hz, 3H); 7.39 (d, J = 8.8 Hz, 1H); 7.35 (d, J = 2.4 Hz, 1H); 7.07 (dd, J = 9.2, 2.8 Hz, 1H); 6.96-6.87 (m, 2H); 6.80 (d, J = 9.6 Hz, 2H); 4.10-4.07 (t, 2H); 3.91 (s, 3H); 2.72-2.69 (t, 2H); 2.48-2.48 (m, 4H); 1.61-1.55 (m, 4H); 1.46-1.43 (m, 2H).

15

Example 43

[6-Hydroxy-2-(2,3,4-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone

20


Dissolve [6-methoxy-2-(2,3,4-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (880 mg, 1.69 mmol) in 100 mL methylene chloride and chill in ice. Add 4.0 mL of neat boron tribromide with swirling and stir in the ice bath for 30 minutes. Allow the mixture to come to room temp and stir for an additional 1 hour. Carefully pour the mixture into a two-phase system consisting of saturated sodium bicarbonate solution and a 3/1 mixture of chloroform/isopropanol. Separate the organic layer, dry over 3Å molecular sieves and evaporate to give 800 mg of slightly impure

25

product. Purify on a silica gel column eluting with 3% methanol/methylene chloride to give 635 mg (74%) of the title compound: ¹H-NMR (CD₃OD, 400 MHz) δ 7.89 (d, J = 8.8 Hz, 1H); 7.69-7.42 (m, 4H); 7.45-7.42 (m, 1H); 7.31 (d, J = 2.4 Hz, 1H); 7.14 (dd, J = 9.2, 2.4 Hz, 1H); 7.02-6.87 (m, 3H); 4.20 (t, J = 5.6 Hz, 2H); 2.84 (t, J = 5.6 Hz, 2H); 2.59-2.59 (m, 4H); 1.71-1.65 (m, 4H); 1.56-1.53 (m, 2H).

Example 44

[2-(2,3-Difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone



10


Charge a flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (2.0 g, 3.7 mmol), 2,3 difluorophenyl boronic acid (1.17 g, 7.4 mmol) palladium dichloride bis(triphenylphosphine) (518 mg, 0.74 mmol) and cesium fluoride (5.06 g, 33.3 mmol) and add 250 mL degassed acetonitrile. Heat the mixture at 85 °C for two hours, cool the reaction and filter off any solids. Purify on an SCX column eluting with 2N ammonia/methanol. Purify further on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to give 1.3 g (70%) of the title compound: ¹H-NMR (CD₃OD, 400 MHz) δ 7.92 (d, J = 8.8 Hz, 1H); 7.54 (dd, J = 8.4, 4.0 Hz, 3H); 7.43 (dd, J = 8.4, 1.6 Hz, 1H); 7.31 (d, J = 2.8 Hz, 1H); 7.09 (dd, J = 9.2, 2.4 Hz, 1H); 7.05-6.92 (m, 3H); 6.79 (d, J = 8.8 Hz, 2H); 4.10 (t, J = 5.6 Hz, 2H); 3.93 (s, 3H); 2.73 (t, J = 5.2 Hz, 2H); 2.50-2.50 (m, 4H); 1.62-1.57 (m, 4H); 1.48-1.43 (m, 2H).

20

Example 45[2-(2,3-Difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone

5 Charge a flask with [2-(2,3-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (1.3 g, 2.6 mmol) and add 200 mL methylene chloride followed by 25 ml of HCl/ether and evaporate to dryness. Dissolve the solid in 200 mL methylene chloride and chill the solution in ice. Add to this solution boron tribromide (4.0 mL, 42.4 mmol) with swirling. Stir the solution at room temperature for 1
10 hour at which point all the starting material is gone. Pour this into a two phase mixture consisting of saturated sodium bicarbonate aqueous phase and a 3/1 mixture of chloroform/isopropanol organic phase and extract using a separatory funnel. Separate the organic phase and dry over 3Å molecular sieves. Purify on a silica column eluting with 0-10% methanol/methylene chloride, collecting the first fraction that contains the product to
15 give 400 mg (32%) of the title compound: ¹H-NMR (CD₃OD, 400 MHz) δ 7.84 (d, J = 8.4 Hz, 1H); 7.55 (d, J = 9.2 Hz, 2H); 7.50 (d, J = 8.8 Hz, 1H); 7.40 (dd, J = 9.2, 1.6 Hz, 1H); 7.25 (d, J = 2.4 Hz, 1H); 7.10-7.03 (m, 2H); 6.99-6.95 (m, 2H); 6.83 (d, J = 9.2 Hz, 2H); 4.12 (t, J = 5.2 Hz, 2H); 2.76-2.73 (m, 2H); 2.58-2.52 (m, 4H); 1.64-1.58 (m, 4H); 1.49-1.45 (m, 2H).

20

Preparation 86-Hydroxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester


25

Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (240 g, 430 mmol) in dichloroethane (1.5 L). Cool to 0 °C. Bubble hydrogen chloride (36 g, 1 mol) into the reaction. Condense boron trichloride (250 g, 2.1 mol) into a jacketed addition funnel and add dropwise into the reaction. Stir

48 – 72 h. Carefully add reaction to a mixture of 5 M sodium hydroxide (700 mL), water (500 mL), and dichloromethane (1 L) at 0 °C. Adjust pH to 7 with 50% aqueous sodium hydroxide. Dilute with 1 M sodium bicarbonate (1.7 L) and dichloromethane (500 mL). Separate organic. Wash aqueous with dichloromethane (1 L). Combine organics and dry over magnesium sulfate, filter, and concentrate *in vacuo*. Slurry material in dichloromethane (200 mL) and obtain 196.2 g of the title compound (87%).

Example 46


[2-(3-Fluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride



Charge a flask with trifluoromethanesulfonic acid 6-hydroxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (500 mg, 0.96 mmol) and add 10 mL water along with 2 mL of 1,2 dimethoxyethane. To this add 3-fluorophenylboronic acid (270 mg, 1.91 mmol), transdichlorobis(triphenylphosphine) palladium II (130 mg, 0.19 mmol) and sodium carbonate (920 mg, 8.64 mmol). Heat the mixture to 80 °C and hold for one hour. Cool and filter the mixture and purify on an SCX column, eluting with 2N ammonia/methanol. Concentrate and purify on a silica column eluting with a 0-10 % 2N ammonia in methanol/methylene chloride gradient. Concentrate and convert to the HCl salt: ¹H-NMR (CDCl₃, 300 MHz) δ 7.76 (d, J = 8.7 Hz, 1H); 7.52-7.41 (m, 5H); 7.21-6.96 (m, 4H); 6.89-6.86 (m, 1H); 6.52 (d, J = 9.0 Hz, 2H); 4.09-4.05 (t, 2H); 2.78-2.78 (m, 2H); 2.56 (s, 4H); 1.67-1.63 (m, 4H); 1.48-1.46 (m, 2H).

Preparation 9

Trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester



5


Dissolve 4-(2-azepan-1-yl-ethoxy)-benzoyl chloride (79.4 g, 249 mmol) and 2,6-dimethoxynaphthalene (37.8 g, 201 mmol) in dichloromethane (800 mL). Cool to -5°C and add aluminum trichloride (134 g, 1 mol). Warm to room temperature and stir overnight. Add chilled water (1.5 L) and stir vigorously for 1 hour. Decant the mixture away from the residue and separate organic. Wash the aqueous layer with dichloromethane (500 mL). Combine with residue from the reaction vessel and wash with saturated aqueous sodium bicarbonate (1 L). Separate the organic after prolonged stirring (2 hours) and wash the aqueous layer with dichloromethane (300 mL). Combine the organic layers and add Darco (30 g), silica gel (30 g), and magnesium sulfate. Filter and concentrate *in vacuo* to give 72.4 g of [4-(2-azepan-1-yl-ethoxy)-phenyl]-(2-hydroxy-6-methoxy-naphthalen-1-yl)-methanone (73%).

Dissolve [4-(2-azepan-1-yl-ethoxy)-phenyl]-(2-hydroxy-6-methoxy-naphthalen-1-yl)-methanone (41.0 g, 88.0 mmol) and triethylamine (28.8 g, 284 mmol) in dichloromethane (400 mL). Cool to -60°C and add trifluoromethanesulphonic anhydride (39.8 g, 141 mmol) in dichloromethane (100 mL). Warm to room temperature and stir. Dilute with saturated aqueous sodium bicarbonate (500 mL) and separate the organic. Wash the aqueous with dichloromethane (200 mL). Combine the organics and wash with saturated aqueous sodium chloride. Dry over magnesium sulfate, filter, and concentrate *in vacuo*. Purify the residue by column chromatography using a silica gel column eluting with a linear gradient beginning with dichloromethane and ending with 30 : 1 dichloromethane : methanol to give 48.6 g of the title compound (96%).

25

Example 47

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[6-methoxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone



5

Dissolve trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxy-naphthalen-2-yl ester (990 mg, 1.8 mmol), 2,4,6-trifluorophenylboronic acid (634 mg, 3.6 mmol), potassium phosphite (2.2 g, 10.8 mmol), tetrakis(triphenylphosphine)palladium (416 mg, 0.4 mmol) in dry DMF (25 mL) and heat at 100 °C for 3 hours. Purify reaction by SCX column and by silica gel chromatography using a 1-3% gradient of methanol in dichloromethane to yield 320 mg (35%) of the title compound: mass spectrum (ion spray) $m/z = 534$ (M+H).

10

Example 48

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[6-hydroxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone

15


Dissolve [4-(2-azepan-1-yl-ethoxy)-phenyl]-[6-methoxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone (634 mg, 1.2 mmol) in dichloromethane (10 mL). Cool to 0 °C, add HCl (2M in ether, 1.2 mL, 2.4 mmol) and stir at room temperature for 15 minutes. Concentrate *in vacuo*. Redissolve the salt in dichloromethane (10 mL) and cool to 0 °C. Add boron tribromide (949 mg, 3.6 mmol) dropwise and bring to room temperature. Stir reaction for 1.5 hour and pour reaction mixture onto ice, saturated sodium bicarbonate (20 mL) and methanol (20 mL). Extract with dichloromethane, combine extracts and wash with water and saturated sodium bicarbonate. Dry with sodium sulfate, filter, and concentrate *in vacuo*. Purify by silica gel chromatography using a 1-3% gradient of methanol in dichloromethane to yield 350 mg (57%) of the title compound: mass spectrum (ion spray) $m/z = 520$ (M+H).

20

25

Example 49

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2-fluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone



5

Dissolve trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester (1.68 g, 3.05 mmol) in 30 mL of acetonitrile and add 2-fluorobenzene boronic acid (0.85 g, 6.10 mmol), trans[dichlorobis(triphenylphosphine)] palladium II (0.43 g, 0.61 mmol) and sonicate briefly. Next add cesium fluoride (4.17 g, 27.45 mmol) and heat to 75 °C for 1 hour. Add Celite and filter. Concentrate the solvent under vacuum, dissolve in methanol and purify on an SCX cartridge, eluting with 2 N ammonia/methanol. Purify further on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to isolate 1.10 g of the title compound (72%).

15

Example 50

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2-fluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-methanone hydrochloride


20

Dissolve [4-(2-azepan-1-yl-ethoxy)-phenyl]-[2-(2-fluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone (550 mg, 1.11 mmol) in 20 mL methylene chloride and cool in an ice bath. Boron tribromide is added (1.5 mL) and allow to come to room temperature. Pour into a two phase solution of saturated sodium bicarbonate and 3/1 chloroform/isopropanol. Separate the organic layer, wash with water and dry over 3Å sieves. Evaporate the solvent and purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to isolate 268 mg of the free base of the title compound (50%). Dissolve the free base in a 1 : 1 mixture of acetonitrile : water. Add an appropriate amount of 5 M hydrochloric acid and lyophilize the mixture to afford the title compound.

25

Example 51

5-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-6-(2-fluoro-phenyl)-naphthalen-2-ol Hydrochloride




5 Dissolve [4-(2-azepan-1-yl-ethoxy)-phenyl]-[2-(2-fluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-methanone (223 mg, 0.48 mmol) in 15 mL tetrahydrofuran. To this solution add 5ml lithium triethylborohydride (1M solution in tetrahydrofuran). Dilute reaction with water and extract with ethyl acetate and concentrate. Dissolve the residue (the alcohol product) in 20 mL methylene chloride and add triethylsilane (0.06 mL, 0.40 mmol) and 1.5 mL trifluoroacetic acid. Concentrate this reaction and purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to give 70 mg (31%) of the free base of the title compound. Dissolve the free base in a 1 : 1 mixture of acetonitrile : water. Add an appropriate amount of 5 M hydrochloric acid and lyophilize the mixture to afford the title compound.

15

Example 52

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[6-methoxy-2-(2,3,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone



20

20 Couple trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester (1.48 g, 2.67 mmol) with 2-bromo-1,3,4-trifluoro-benzene (1.13 g, 5.35 mmol) in a procedure similar to the preparation of [6-hydroxy-2-(2,3,5-trifluoro-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone to give 0.66 g (46%) of the title compound: mass spectrum (ion spray) $m/z = 534.4$ (M+H).

25

Example 53

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[6-hydroxy-2-(2,3,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone

5


Demethylate [4-(2-azepan-1-yl-ethoxy)-phenyl]-[6-methoxy-2-(2,3,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone (0.66 g, 1.24 mmol) with BBr_3 in a procedure similar to the preparation of [4-(2-azepan-1-yl-ethoxy)-phenyl]-[6-hydroxy-2-(2,4,6-trifluoro-phenyl)-naphthalen-1-yl]-methanone to give 0.53 g (82%) of the title compound.

10 Analytical data obtained for the corresponding HCl salt: mass spectrum (ion spray) $m/z = 520.3$ (M-Cl).

Example 54

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2,4-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone

15



Couple trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester (1.4 g, 2.5 mmol) and 2,4-difluorophenyl boronic acid (1.2 g, 7.6 mmol) by the procedure described for the preparation of 2-(2,4-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone to give 1.1 g (85%) of the title compound: mass spectrum (ion spray) $m/z = 516.3$ (M+H).

20


Example 55

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2,4-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-methanone hydrochloride

5 Demethylate [4-(2-azepan-1-yl-ethoxy)-phenyl]-[2-(2,4-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone (1.1 g, 2.1 mmol) with BBr_3 (1.0 mL, 10.5 mmol) by the procedure described for the preparation of [2-(2,4-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone. Purify on silica gel (0% to 5% methanol in methylene chloride) to yield 790 mg (75%) of the free base of the
10 title compound: mass spectrum (ion spray) $m/z = 502.3$ (M+H). Convert to the hydrochloride salt.

Example 56

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2,6-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone



Charge a flask with trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester (3.9 g, 7.06 mmol), 2,6-difluorophenyl boronic acid (2.23 g, 14.12 mmol), potassium phosphate (9.0 g, 42.20 mmol) and
20 tetrakis(triphenylphosphine)palladium (0) (1.63 g, 1.40 mmol) followed by 125 mL dry DMF. Heat the mixture under nitrogen at 100 °C for 90 minutes. Cool, filter, evaporate the solvent and purify on an SCX cartridge, eluting with 2N ammonia/methanol. Purify further on a silica gel column eluting with 0-10% methanol/methylene chloride. The yield
25 is 2.5 g (70%): $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.90 (d, $J = 8.4$ Hz, 1H); 7.66-7.61 (m, 3H); 7.39 (d, $J = 8.4$ Hz, 1H); 7.23-7.22 (m, 1H); 7.18-7.08 (m, 2H); 6.79-6.74 (m, 4H); 4.08-4.05 (t, 2H); 3.95 (s, 3H); 2.96-2.89 (t, 2H); 2.78-2.75 (m, 4H); 1.66-1.59 (m, 8H).


Example 57

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2,6-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-methanone

- 5 Convert [4-(2-azepan-1-yl-ethoxy)-phenyl]-[2-(2,6-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone (2.5 g, 4.8 mmol) into the hydrochloride salt and charge a flask with the solid salt. Dissolve the material in 200 mL methylene chloride and chill in ice. Add to this mixture boron tribromide (5.0 mL, 53.0 mmol) while swirling. Stir the reaction at room temperature for one hour and pour into a two phase system of saturated sodium bicarbonate and an organic layer consisting of a 3/1 mixture of
- 10 chloroform/isopropanol. Shake to extract the product, separate the organic layer, dry over 3 Å molecular sieves and evaporate the solvent under vacuum. Purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to give 1.3 g (54%) of the title compound: ¹H-NMR (CDCl₃, 400 MHz) δ 7.79-7.74 (d, 1H); 7.58 (d, J = 8.4
- 15 Hz, 2H); 7.50 (d, J = 8.8 Hz, 1H); 7.33-7.30 (d, 1H); 7.17 (d, J = 2.4 Hz, 1H); 7.16-7.08 (m, 1H); 6.99-6.95 (dd, 1H); 6.77-6.73 (m, 2H); 6.68 (d, J = 9.2 Hz, 2H); 4.11 (t, J = 6.0 Hz, 2H); 3.05-2.99 (t, 2H); 2.90-2.84 (m, 4H); 1.71-1.71 (m, 4H); 1.63-1.60 (m, 4H).

Example 58

- 20 [4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2,5-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone



- 25 Dissolve trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester (2.00 g, 3.63 mmol) in 5 mL of degassed acetonitrile and add 2,5-difluorophenyl boronic acid (1.15 g, 7.26 mmol), trans[dichlorobis(triphenylphosphine)] palladium II (0.51 g, 0.73 mmol) and sonicate briefly. Next add cesium fluoride (4.96 g, 32.76 mmol) and heat to 75 °C for one hour.

Add Celite and filter. Concentrate the solvent under vacuum, dissolve in methanol and purify on an SCX cartridge, eluting with 2N ammonia/methanol to give 1.74 g (93%) of the title compound.

5

Example 59


[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[2-(2,5-difluoro-phenyl)-6-hydroxy-naphthalen-1-yl]-methanone

Dissolve [4-(2-azepan-1-yl-ethoxy)-phenyl]-[2-(2,5-difluoro-phenyl)-6-methoxy-naphthalen-1-yl]-methanone (1.74 g, 3.37 mmol) in 20 mL methylene chloride and chill in ice. Add to this solution 2.0 mL of boron tribromide (5.3 g, 21.2 mmol) and allow to come to room temperature. Pour into a two phase solution of saturated sodium bicarbonate and 3/1 chloroform/isopropanol. Separate the organic layer, wash with water and dry over 3A sieves. Evaporate the solvent and purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient. Evaporate the solvent to give 780 mg (46%) of the title compound: ¹H-NMR (CDCl₃, 300 MHz) δ 7.79 (d, J = 8.7 Hz, 1H); 7.60-7.55 (m, 3H); 7.41 (dd, J = 8.7, 1.8 Hz, 1H); 7.26-7.21 (m, 1H); 7.04-6.82 (m, 4H); 6.71-6.68 (m, 2H); 4.14-4.14 (m, 2H); 3.03-2.97 (m, 2H); 2.95-2.88 (m, 4H); 1.73-1.58 (m, 8H).

20

Example 60

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[6-methoxy-2-(2,3,5-trifluoro-phenyl)-naphthalen-1-yl]-methanone



25

Dissolve trifluoromethanesulfonic acid 1-[4-(2-azepan-1-yl-ethoxy)-benzoyl]-6-methoxynaphthalen-2-yl ester (2.60 g, 6.53 mmol) in 200 mL acetonitrile and add to this bis(pinacolato)diboron (1.5 g, 7.96 mmol), bis(tricyclohexylphosphine)palladium (0)

(0.72 g, 1.50 mmol) and cesium fluoride (7.33 g, 67.0 mmol). Heat the reaction to 100 °C until LC/MS indicates all starting material is consumed. Add to this mixture 1-bromo-2,3,5-trifluorobenzene (2.00 g, 13.06 mmol) and another 720 mg of palladium catalyst and heat at 80 °C for 24 hours. Filter the reaction, concentrate and purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to give 1.85 g (53%) of the title compound.


Example 61

[4-(2-Azepan-1-yl-ethoxy)-phenyl]-[6-hydroxy-2-(2,3,5-trifluoro-phenyl)-naphthalen-1-yl]-methanone

Dissolve [4-(2-azepan-1-yl-ethoxy)-phenyl]-[6-methoxy-2-(2,3,5-trifluorophenyl)-naphthalen-1-yl]-methanone (2.85 g, 5.34 mmol) in 50 mL methylene chloride and cool to 0 °C. Add boron tribromide (3.0 mL, 31.7 mmol) and allow to come to room temperature. Pour into a two phase system of saturated sodium bicarbonate and 3/1 chloroform/isopropanol. Wash the organic layer with brine and dry over 3Å molecular sieves. Concentrate to give 2.63 g (95%) of the title compound.

Preparation 10

Trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester



Dissolve (2,6-dimethoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (56.0 g, 123 mmol) in chloroform (500 mL). Cool to 0 °C. Add boron trichloride (150 mL, 150 mmol, 1 M solution in dichloromethane) and stir 2 hours. Warm to room temperature and stir 1.5 hours. Add additional boron trichloride (50 mL, 50 mmol) after cooling to 0 °C. Warm to room temperature and stir overnight. Carefully add ice and saturated aqueous sodium bicarbonate. Separate organic and wash aqueous three

times with a 3 : 1 dichloromethane : isopropanol mixture. Concentrate *in vacuo* and dissolve in dichloromethane. Dry over sodium sulfate, decant, and concentrate *in vacuo*. Slurry in ether and filter, rinsing with hexanes to give 49.4 g of (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (99%).


- 5 Dissolve (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (12 g, 29.6 mmol) in tetrahydrofuran (200 mL). Add lithium aluminum hydride (3.0 g, 78.0 mmol) and heat the reaction to reflux. Allow to cool to room temperature and add ice. Adjust the pH of the mixture to 7 with 5 M hydrochloric acid. Dilute with water (500 mL). Wash the mixture four times with dichloromethane
10 (500 mL each wash). Combine the organics, dry over sodium sulfate, decant, and concentrate *in vacuo* to give 1-{hydroxy-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methyl}-6-methoxy-naphthalen-2-ol.

- Redissolve in chloroform and add trifluoroacetic acid (5.0 mL, 64.9 mmol) and triethylsilane (10.0 mL, 62.6 mmol). Heat the reaction to reflux for 1 hour. Cool to room
15 temperature and dilute with saturated aqueous sodium bicarbonate (300 mL). Extract the organic and wash the aqueous twice with dichloromethane (300 mL each wash). Combine the organics, dry over sodium sulfate, decant, and concentrate *in vacuo*. Isolate a residue containing 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol. Purify the residue on an SCX column, eluting the impurities with methanol, then eluting
20 the product with 2N ammonia/methanol.

- Dissolve 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol in dichloroethane (300 mL) and add N-phenylbis(trifluoromethanesulfonimide) (15.0 g, 42.0 mmol). Add triethylamine (20 mL, 143.5 mmol) and heat to reflux for 6 hours. Concentrate *in vacuo* and purify the residue by column chromatography using a silica gel
25 column eluting with a linear gradient beginning with dichloromethane and ending with 20 : 1 dichloromethane : methanol to give 13.6 g of the title compound (88%).

Example 62

1-(2-{4-[2-(2,5-Difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



5

Charge a flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester (1.0 g, 1.91 mmol) and add 20 mL degassed acetonitrile. To this solution add 2,5-difluorophenyl boronic acid (0.6 g, 3.82 mmol), transdichlorobis(triphenylphosphine) palladium II, (270 mg, 0.38 mmol) and cesium fluoride (2.61 g, 17.2 mmol). Sonicate the mixture briefly and heat to 75 °C. After 3 hours add an additional small amount of the acid, the catalyst and the cesium fluoride and heat overnight. In the morning filter the mixture and run through and SCX column eluting with 2N ammonia in methanol. Purify further on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient. Concentrate to give 430 mg (46%) of the title compound: ¹H-NMR (CDCl₃, 300 MHz) δ 7.85 (d, J = 9.3 Hz, 1H); 7.73 (d, J = 8.7 Hz, 1H); 7.33 (d, J = 8.4 Hz, 1H); 7.18 (d, J = 2.7 Hz, 1H); 7.11-6.89 (m, 4H); 6.86-6.82 (m, 2H); 6.73-6.69 (m, 2H); 4.34-4.19 (d, H); 4.04-3.99 (t, 2H); 3.93 (s, 3H); 2.72 (t, J = 6.3 Hz, 2H); 2.47 (t, J = 5.1 Hz, 4H); 1.58 (qui, J = 5.4 Hz, 4H); 1.46-1.41 (m, 2H).

20

Example 63

6-(2,5-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol hydrochloride


Dissolve 1-(2-{4-[2-(2,5-difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine in 20 mL acetonitrile and chill in an ice bath. Add 1.5 mL of boron tribromide with swirling and allow to warm to room temperature. Pour this mixture into a two-phase mixture of saturated sodium bicarbonate solution and a 3/1 mixture of chloroform/isopropanol. Wash the organic layer with water and dry over 3 Å

25

molecular sieves. Concentrate the organic layer and purify on a silica gel column, eluting with a 0-10% methanol/methylene chloride gradient. Evaporate the solvent and convert the compound to the salt with HCl to give 369 mg (82%) of the title compound: ¹H-NMR (CDCl₃, 300 MHz) δ 7.77 (d, J = 8.7 Hz, 1H); 7.61 (d, J = 8.1 Hz, 1H); 7.28-7.25 (m, 1H); 7.11-6.94 (m, 4H); 6.89-6.83 (m, 1H); 6.74 (d, J = 8.7 Hz, 2H); 6.57-6.54 (m, 2H); 4.31-4.10 (d, 2H); 4.04 (t, J = 6.0 Hz, 2H); 2.80-2.80 (m, 2H); 2.59-2.59 (m, 4H); 1.68-1.65 (m, 4H); 1.48-1.46 (m, 2H).

Example 64

10 1-(2-{4-[2-(2,4-Difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester (1.00 g, 1.91 mmol) in 20 mL of degassed acetonitrile and add 2,4-difluorophenyl boronic acid (0.60 g, 3.82 mmol), trans[dichlorobis(triphenylphosphine)] palladium II (0.27 g, 0.38 mmol) and sonicate briefly. Next add cesium fluoride (2.61 g, 17.19 mmol) and heat to 75 °C for one hour. Add Celite and filter. Concentrate the solvent under vacuum, dissolve in methanol and purify on an SCX cartridge, eluting with 2N ammonia/methanol to isolate the title compound.

Example 65


25 6-(2,4-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol hydrochloride

Dissolve 1-(2-{4-[2-(2,4-difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine (0.72 g, 1.48 mmol) in 30 mL methylene chloride and chill in

ice. Add to this solution 2.0 mL of boron tribromide (21.2 mmol) and allow to come to room temperature. Pour into a two phase solution of saturated sodium bicarbonate and 3/1 chloroform/isopropanol. Separate the organic layer, wash with water and dry over 3 Å sieves. Evaporate the solvent and purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient. Evaporate the solvent to yield 300 mg (43%) of the free base of the title compound. Dissolve the free base in a 1 : 1 mixture of acetonitrile : water. Add an appropriate amount of 5 M hydrochloric acid and lyophilize the mixture to afford the title compound.

Example 66

10 1-(2-{4-[2-(4-Fluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester (1.0 g, 1.91 mmol), 4-fluorophenyl boronic acid (3.8 g, 3.8 mmol), trans[dichlorobis(triphenylphosphine)] palladium II (266 mg, 0.38 mmol) and cesium fluoride (2.6 g, 17.1 mmol) in 125 mL degassed acetonitrile and heat at 85 °C for 8 hours. Cool and filter and purify on an SCX column and elute with 2 N ammonia/methanol. Evaporate to an oil and purify on a silica gel column eluting with a gradient of 0-10% methanol/methylene chloride: mass spectrum (ion spray) $m/z = 470$ (M+H).


Example 67

25 6-(4-Fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol hydrochloride

Dissolve 1-(2-{4-[2-(4-fluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine (500 mg, 1.06 mmol) in 250 mL methylene chloride and chill in ice. To this add 1.0 mL boron tribromide with swirling and allow the mixture to come to room temperature. After one hour add another 1.0 mL of the boron tribromide, then
5 after 30 minutes add another 0.5 mL of the bromide and stir for another 30 minutes. Pour the reaction into a two-phase system of saturated sodium bicarbonate and an organic layer consisting of a 3/1 mixture of chloroform/isopropanol. Shake in a separatory funnel, separate the organic layer and dry over 3 Å molecular sieves. Evaporate the solvent and purify on a silica column eluting with a gradient of 0-10% methanol/methylene chloride
10 to give 300 mg of the free base of the title compound (62%). Convert the free base to the salt by dissolving in acetonitrile and adding hydrochloric acid and lyophilizing the resulting solution.

Example 68

15 1-(2-{4-[2-(2-Fluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester (1.0 g, 1.9 mmol), 2-fluorophenyl boronic acid (532 mg, 3.8 mmol), trans[dichlorobis(triphenylphosphine)] palladium II (266 mg, 0.38 mmol) and cesium fluoride (2.6 g, 17.1 mmol) in 150 mL degassed acetonitrile and heat at 85 °C for 2 hours. Cool the reaction, filter and purify on an SCX-column, eluting with 2N ammonia/methanol. Concentrate and purify on a silica column eluting with 10-10%
20 gradient of methanol/methylene chloride to give 560 mg (63%) of the title compound: mass spectrum (ion spray) $m/z = 470$ (M+H).
25

Example 69

6-(2-Fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol
hydrochloride


5

Dissolve 1-(2-{4-[2-(2-fluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-
phenoxy}-ethyl)-piperidine (560 mg, 1.2 mmol) in 250 mL acetonitrile and chill in ice.
Add 2.0 mL of boron tribromide with swirling, stir one hour and allow to come to room
temp. Pour the reaction into a two-phase system consisting of saturated sodium
10 bicarbonate and an organic layer of a 3/1 mixture of chloroform/methanol. Shake in a
separatory funnel, separate the organic layer and dry over molecular sieves. Evaporate the
solvent and purify on an SCX column, eluting with 2N ammonia/methanol. Evaporate
the solvent to an oil and purify on a silica column eluting with a 0-10%
methanol/methylene chloride gradient to give 220 mg of the free base of the title
15 compound (48%). Convert to the HCl salt by dissolving in acetonitrile and adding
hydrochloric acid and lyophilizing.

Example 70

1-(2-{4-[2-(3-Fluorophenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-
piperidine

20



Charge a flask with trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-
yl-ethoxy)-benzyl]-naphthalen-2-yl ester (2.0 g, 3.82 mmol), 3-fluorophenyl boronic acid
25 (1.07 g, 7.64 mmol), trans-dichlorobis(triphenylphosphine)palladium II (536 mg, 0.76
mmol) and cesium fluoride (5.2 g, 34.4 mmol) along with 100 mL degassed acetonitrile
and heat at 85 °C for 4 hours or until all the starting triflate is consumed. Cool the
reaction, filter and purify on an SCX column eluting with 2N ammonia/methanol. The
crude yield is 1.5 g (83%). Further purify the crude material on a silica column, eluting

with 3% methanol/methylene chloride to give 1.1 g of the title compound (63%): ¹H-NMR (CDCl₃, 400 MHz) δ 7.81 (d, J = 9.6 Hz, 1H); 7.73 (d, J = 8.4 Hz, 1H); 7.39 (d, J = 8.4 Hz, 1H); 7.28-7.25 (m, 1H); 7.19 (d, J = 2.4 Hz, 1H); 7.11-7.06 (m, 2H); 7.04-7.01 (m, 2H); 6.88 (d, J = 9.2 Hz, 2H); 6.75 (dd, J = 6.4, 2.4 Hz, 2H); 4.34 (s, 2H); 4.07 (t, J = 6.0 Hz, 2H); 3.93 (s, 3H); 2.81 (t, J = 6.0 Hz, 2H); 2.57-2.57 (m, 4H); 1.67-1.61 (m, 4H); 1.48-1.46 (m, 2H).

Example 71

6-(3-Fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol
hydrochloride


10

Charge a flask with 1-(2-{4-[2-(3-fluorophenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine (1.1 g, 2.3 mmol) dissolved in 250 mL methylene chloride and chill in ice. Add 6.0 mL of neat boron tribromide in portions with stirring and stir the reaction in ice for one hour then at room temperature for 2 hours. Pour the reaction into a two-phase mixture consisting of saturated sodium bicarbonate and an organic phase of 3/1 chloroform/isopropanol. Extract the compound into the organic phase using a separatory funnel, separate the phases and dry the organic layer over 3 Å molecular sieves. Evaporate and purify on a silica column eluting with 3% methanol/methylene chloride. Convert to the hydrochloride salt and lyophilize to yield 650 mg (57%) of the title compound: ¹H-NMR (data reported for the free base) (CDCl₃, 400 MHz) δ 7.73 (d, J = 9.6 Hz, 1H); 7.61 (d, J = 8.0 Hz, 1H); 7.32-7.30 (m, 1H); 7.28-7.24 (m, 1H); 7.15 (d, J = 2.0 Hz, 1H); 7.04-6.94 (m, 4H); 6.79 (d, J = 8.4 Hz, 2H); 6.62-6.59 (m, 2H); 4.28 (s, 2H); 4.13 (t, J = 5.6 Hz, 2H); 2.92-2.92 (m, 2H); 2.72-2.64 (m, 4H); 1.74 (d, J = 4.8 Hz, 4H); 1.51-1.51 (m, 2H).

20
25

Example 72

1-(2-{4-[6-Methoxy-2-(2,3,4,5-tetrafluoro-phenyl)-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



5

Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester (259 mg, 0.49 mmol), bis(pinacolato)diboron (151 mg, 0.59 mmol), bis(tricyclohexylphosphine)palladium (0) (75 mg, 0.11 mmol) and cesium fluoride (764 mg, 5.03 mmol) in 20 mL degassed acetonitrile and heat at 100 °C under nitrogen in a sealed vial. The reaction is complete in 10 minutes. Cool and add 1-bromo-2,3,4,5-tetrafluorobenzene (224 mg, 0.99 mmol) along with 10 mL acetonitrile, seal the vial, purge with nitrogen and heat at 80 °C for 2 hours. Cool, filter and purify on an SCX column eluting with 2N ammonia/methanol. Evaporate the solvent and purify the resulting oil on a silica column eluting with 3% methanol/methylene chloride to give 188 mg of the title compound (73%).

15

Example 73

5-[4-(2-Piperidin-1-yl-ethoxy)-benzyl]-6-(2,3,4,5-tetrafluoro-phenyl)-naphthalen-2-ol hydrochloride

20

Dissolve 1-(2-{4-[6-methoxy-2-(2,3,4,5-tetrafluoro-phenyl)-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine (180 mg, 0.34 mmol) in 50 mL methylene chloride and chill in ice. Add 2.0 mL boron tribromide and stir in ice for 1 hour. Pour this mixture into a 2-phase mixture consisting of saturated sodium bicarbonate and an organic layer of 3/1 chloroform/isopropanol. Shake in a separatory funnel, separate the organic layer, wash it with brine and dry over molecular sieves. Evaporate the solvent and purify on a silica column eluting first with pure methylene chloride, then with 3%


25

methanol/methylene chloride. Repeat the purification to give 45 mg of the free base of the title compound (26%). The free base is converted to the hydrochloride salt by dissolving in acetonitrile, adding HCl and lyophilizing: mass spectrum (ion spray) m/z = 510 (M-Cl).

5

Preparation 11

(4-Bromo-phenyl)-(2-piperidin-1-yl-ethyl)-carbamic acid tert-butyl ester




10

Dissolve (4-bromo-phenyl)-carbamic acid tert-butyl ester (3.0 g, 11.0 mmol) in N,N-dimethylformamide (30 mL). Add sodium hydride (1.1 g, 27.6 mmol) and stir at room temperature. Add 1-(2-chloroethylpiperidine) monohydrochloride (3.0 g, 16.5 mmol). Stir overnight at room temperature and then overnight at 60 °C. Cool to room temperature and dilute with ethyl acetate and water. Separate the organic layer and wash the aqueous with ethyl acetate. Combine the organics and wash with saturated aqueous sodium chloride. Dry over magnesium sulfate, filter, and concentrate *in vacuo*. Purify the residue by column chromatography using a silica gel column eluting with a linear gradient beginning with dichloromethane and ending with 9 : 1 dichloromethane : methanol to give 1.2 g of the title compound.

20

Example 74

1-(2-{4-[2-(2,6-Difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



25

Dissolve trifluoromethanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-yl ester (1.50 g, 2.86 mmol) in 50 mL of acetonitrile and add 2,6-difluorophenyl boronic acid (0.90 g, 5.73 mmol), tetrakis(triphenylphosphine)palladium(0) (0.66 g, 0.57 mmol). Next add potassium phosphate (3.64 g, 17.16 mmol) and heat to 80 °C for one hour. Add Celite and filter. Concentrate the solvent under vacuum to a dark oil, dissolve in methanol and purify on an SCX cartridge, eluting with 2N ammonia/methanol. Purify further on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient. Evaporate the solvent to yield 800 mg (58%) of the title compound.


Example 75

6-(2,6-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol hydrochloride

Dissolve 1-(2-{4-[2-(2,6-difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine (800 mg, 1.64 mmol) in 20 mL methylene chloride and cool in an ice bath. To this solution add 2.0 mL boron tribromide (21.2 mmol) and allow to come to room temperature. Pour into a two phase solution of saturated sodium bicarbonate and 3/1 chloroform/isopropanol. Separate the organic layer, wash with water and dry over 3 Å sieves. Evaporate the solvent and purify on a silica gel column eluting with a 0-10% methanol/methylene chloride gradient to give 670 mg (86%) of the free base of the title compound. Dissolve the free base in a 1 : 1 mixture of acetonitrile : water. Add an appropriate amount of 5 M hydrochloric acid and lyophilize the mixture to afford the title compound.

Example 76

1-(2-{4-[2-(2,3-Difluoro-phenyl)-6-methoxy-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine



5

Using the method described in the preparation of 1-(2-{4-[6-methoxy-2-(2,3,4,5-tetrafluoro-phenyl)-naphthalen-1-ylmethyl]-phenoxy}-ethyl)-piperidine, prepare the title compound in 49% yield: mass spectrum (ion spray) $m/z = 488$ (M+H).

10

Example 77

6-(2,3-Difluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol hydrochloride

Using the method described in the preparation of 5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-6-(2,3,4,5-tetrafluoro-phenyl)-naphthalen-2-ol hydrochloride, obtain the title compound in 39% yield: mass spectrum (ion spray) $m/z = 474$ (M+H).

15

Formulation (Pharmaceutical Composition)

Because the free base form of a compound of formula I contains a basic moiety (i.e., amino), said compound may be formulated as a pharmaceutical acid addition salt, e.g., as the hydrochloride salt or as a salt described in "Handbook of Pharmaceutical Salts: Properties, Selection and Use", Weinheim, New York: VHCA; Wiley-VCH, 2002.

20

The present pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients. In making the formulations of the present invention, the active ingredient (a formula I compound) will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a

25

solid, semisolid or liquid material that acts as a vehicle, excipient or medium for the active ingredient.

Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.

Biological Assays

Ishikawa Cell Proliferation Assay: This assay measures cell proliferation (using an alkaline phosphatase readout) in both an agonist mode in the presence of a compound of the present invention alone, and in an antagonist mode in which the ability of a compound of the present invention to block estradiol stimulation of growth is measured.

Ishikawa human endometrial tumor cells are maintained in MEM (minimum essential medium, with Earle's salts and L-Glutamine, Gibco BRL, Gaithersburg, MD), supplemented with 10% fetal bovine serum (FBS) (V/V), (Gibco BRL). One day prior to assay, growth media is changed to assay medium, DMEM/F-12 (3:1) (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, 3:1 Mixture, phenol red-free, Gibco BRL) supplemented with 5% dextran coated charcoal stripped fetal bovine serum (DCC-FBS) (Hyclone, Logan, UT), L-Glutamine (2mM), MEM sodium pyruvate (1 mM), HEPES (N-[2-hydroxyethyl]piperazine-N' - [2-ethanesulfonic acid] 2 mM) all from Gibco BRL). After an overnight incubation, Ishikawa cells are rinsed with Dulbecco's Phosphate Buffered Saline (1X) (D-PBS) without Ca^{+2} and Mg^{+2} (Gibco BRL), and trypsinized by a 3 minute incubation with 0.25% Trypsin/EDTA, phenol red-free (Gibco BRL). Cells are resuspended in assay medium and adjusted to 250,000 cells/mL. Approximately 25,000 cells in a 100ul media are added to flat-bottom 96 wells microculture plates (Costar 3596) and incubated at 37°C in a 5% CO_2 humidified incubator for 24 hours. The next day, serial dilutions of compounds are prepared in assay medium (at 6 times the final concentration in the assay). The assay is run in dual mode, agonist and antagonist modes.

For the agonist mode, plates receive 25 μ l/well of assay medium followed by 25 μ l/well of a diluted compound of the present invention (at 6x the final concentrations). For the antagonist mode, plates receive 25 μ l/well of 6 nM E₂ (β -Estradiol, Sigma, St. Louis, MO) followed by 25 μ l/well of a diluted compound of the present invention (at 6x the final concentrations). After an additional 48-hour incubation at 37°C in a 5% CO₂ humidified incubator, media is aspirated from wells and 100 μ l fresh assay medium is added to each microculture. Serial dilutions of compounds are prepared and added to the cells as described above. After an additional 72 hour incubation at 37°C in a 5% CO₂ humidified incubator, the assay is quenched by removing media and rinsing plates twice in Dulbecco's Phosphate Buffered Saline (1X) (D-PBS) (Gibco BRL). The plates are dried for 5 minutes and frozen at -70°C for at least 1 hour. The plates are then removed from the freezer and allowed to thaw at room temperature. To each well, 100 μ l of 1-Step™ PNPP (Pierce Chemical Company, Rockford, IL) is added. After a 20-minute incubation, plates are read on a spectrophotometer at 405nm.

The data is fitted to a linear interpolation to derive EC50 (for agonist mode) or IC50 (for antagonist mode) values. For the antagonist mode, a % efficacy for each compound is calculated versus E2 (1nM) alone. For the agonist mode, a % efficacy for each compound is calculated versus the response to tamoxifen.

3-Day Rat Uterus Antagonist Assay: This model for uterine antagonism utilizes immature (3 week old) female rats that are highly sensitive to estrogenic stimulation of the uterus given that their circulating estrogen levels are prepubertal. The uteri from immature rats are fully responsive to exogenous estrogen, yet are quiescent in the absence of exogenous estrogen. Administration of exogenous estrogen to immature rats produces a reliable elevation of uterine weight, which can be used to study uterine antagonist effects. The rats are treated with both estradiol and 4 different concentrations of a compound of the present invention for 3 days and then uterine wet weights are measured.

Nineteen to twenty-one day old (or 45-50g) female rats are orally treated with E2 (0.1 mg/kg, a maximal stimulatory estrogenic stimulus for reliably increasing uterine weight) and 10, 1.0, 0.1 and 0.01 mg/kg test compound for 3 days, 6 rats per group. Test compounds are dissolved in 20% β -hydroxycyclodextrin and administered by oral gavage in a volume of 0.2 mL daily (15 min. prior to the ethynyl estradiol gavage). A vehicle

control, E2 alone and E2 + raloxifene are also done as controls. The animals are fasted overnight following the final dose. On the following morning, the animals are weighed, then euthanized (by carbon dioxide asphyxiation) and the uteri rapidly collected (via a mid-line ventral incision) and weighed.

- 5 Uterine weight/body weight ratios (UWR) are calculated for each animal. The percent inhibition of the estrogen-induced response is then calculated by the following formula: percent inhibition = $100 \times (\text{UWR}_{\text{estrogen}} - \text{UWR}_{\text{test compound}} / \text{UWR}_{\text{estrogen}} - \text{UWR}_{\text{control}})$. ED50 values are derived from a semi-log regression analysis of the linear aspect of the dose response curve. Both the UWR data and the percent inhibition
10 data were statistically analyzed by one way analysis of variance (ANOVA) with post-hoc testing by Fisher's PLSD when indicated by a $p \leq 0.05$. Statistical analyses are performed using the Statview® 4.0 software package.

- Morphine withdrawal, rat hot flash model:* Simpkins et al. (1983) first published
15 morphine withdrawal in the rat as a putative model for hot flashes, based on observations highlighting the similarity of symptoms of gonadal steroid withdrawal to those of opioid withdrawal. Although less severe, the signs and symptoms associated with clinical hot flashes, or estrogen deficiency, in the rat parallel those produced by naloxone-precipitated withdrawal in morphine dependent rats, including: 1) an increase in tail skin temperature,
20 2) a surge in luteinizing hormone and 3) an increase in heart rate. Each of these responses are associated with an increase in sympathetic outflow, which is a current mechanistic hypothesis for hot flashes. As a corollary, morphine addicted humans show a withdrawal pattern suggesting increased sympathetic outflow and symptoms that include hot flashes. A key feature of animal models, is that they mimic the treatment efficacy observed with
25 the human disease. The morphine withdrawal hot flash model, either in its originally described form, or with the modifications described herein, is responsive to agents typically used in the treatment of human hot flashes. This includes various forms of estrogen (Simpkins et al., 1983; LRL data), clonidine (LRL data), tibolone (LRL data), and medroxyprogesterone (LRL data). Furthermore, the model is sensitive to agents
30 known to be associated with the induction of hot flashes in postmenopausal women.

A modification of the original procedure of Simpkins et al. (1983) is used which employs ovariectomized Sprague-Dawley rats. Animals at 60 days of age (or 200-225

grams) are ovariectomized, and allowed a 14-day rest period to insure surgical recovery and clearance of endogenous ovarian hormones. Administration of a compound of the present invention (po or sc) is initiated on day 14 post-ovariectomy in a volume of 1 ml/kg. Once daily administration of test compound continues through the end of the experiment. On days 15 and 17 post-ovariectomy, the rats are lightly anesthetized with isoflurane and a single 75 mg morphine (free base) pellet is surgically implanted subcutaneously.

On day 21 post-ovariectomy, animals are given ketamine (80 mg/kg; IM) 2-hours after final administration of the test compound. Following induction of the anesthesia, rats are then placed in individual plexiglass cages and temperature sensitive probes are applied to the dorsal side of the tail base. Temperature monitoring is initiated 30 minutes after administration of ketamine and is recorded every 15 seconds for a 1-hr period. To induce morphine withdrawal, 1 mg/kg naloxone is given subcutaneously 15 minutes after start of temperature monitoring. A sharp rise in tail skin temperature typically occurs within 5 minutes post-naloxone injection, and two quantitative endpoints are made: 1) tail skin temperature at 15 min post-naloxone, and 2) area under the temperature response curve for the 45-min post-naloxone measurement period. Following the 1-hour temperature collection period, the animals are sacrificed by decapitation and trunk blood is collected for assessment of serum LH levels (by ELISA). Uteri are also removed at this time, and wet weight recorded.

Representative compounds of formula I were tested at or below 30 mg/kg PO and caused an attenuation of tail skin temperature increase, as measured by temperature change 15 minutes post naloxone injection or AUC over 45 minutes post naloxone administration.

Utilities

As previously stated, the compound of formula I is useful in the treatment of vasomotor symptoms, particularly hot flashes, in a woman, particularly a post-menopausal woman. Typically, the compounds of the present invention are employed in a woman who has suffered at least one vasomotor symptom event. Thus, the compounds of the present invention are most typically employed to reduce the likelihood that the patient will further incur vasomotor symptoms.


Dose

The specific dose administered is determined by the particular circumstances surrounding each situation. These circumstances include, the route of administration, the
5 prior medical history of the recipient, the symptom being treated, the severity of the symptom being treated, and the age of the recipient. The recipient patient's attending physician should determine the therapeutic dose administered in light of the relevant circumstances.

Generally, an effective minimum daily dose of a compound of formula I will
10 exceed about 5 mg. Typically, an effective maximum daily dose will not exceed about 350 mg. The exact dose may be determined, in accordance with the standard practice in the medical arts of "dose titrating" the recipient; that is, initially administering a low dose of the compound, and gradually increasing the dose until the desired therapeutic effect is observed.

WE CLAIM:

1. A compound of formula I:



5

wherein:

m is 0, 1 or 2;

n is 1, 2, 3, 4 or 5;

R is H or methyl provided that if m is 1 or 2, then R must be H and that if

- 10 m is 0, then R must be methyl;

R^1 is H, $\text{SO}_2(\text{n-C}_4\text{-C}_6 \text{ alkyl})$ or COR^2 ;

X is O or NR^3 ;

X^1 is O, CH_2 or C=O ;

R^2 is $\text{C}_1\text{-C}_6$ alkyl; $\text{C}_1\text{-C}_6$ alkoxy; NR^4R^{4a} ; phenoxy; or phenyl optionally

- 15 substituted with halo;

R^3 is H or $\text{C}_1\text{-C}_6$ alkyl; and

R^4 and R^{4a} are independently H, $\text{C}_1\text{-C}_6$ alkyl or phenyl; or a pharmaceutical acid addition salt thereof.


- 20 2. The compound of claim 1 wherein m is 1 or 2.

3. The compound of claim 1 or claim 2 wherein R^1 is H or COR^2 and R^2 is $\text{C}_1\text{-C}_4$ alkyl, NHCH_3 or phenyl.

- 25 4. The compound of any one of claims 1-3 wherein R^1 is H.

5. The compound of any one of claims 1-4 wherein X is O.
6. The compound of any one of claims 1-5 wherein X¹ is O or CH₂.
- 5 7. The compound of any one of claims 1-6 wherein X¹ is O and m is 1.
8. The compound of any one of claims 1-7 wherein n is 1, 2 or 3.
- 10 9. The compound of any one of claims 1-8 wherein n is 1 or 2.
10. The compound of any one of claims 1-9 wherein n is 2 and the corresponding fluoro moieties are at the 3- and 5-positions.
- 15 11. The compound of any one of claims 1-9 wherein n is 1 and the corresponding fluoro moiety is at the 4-position.
12. The hydrochloride salt of a compound of any one of claims 1-11.
- 20 13. A method for treating one or more vasomotor symptoms comprising administering to a woman in need thereof an effective amount of a compound of any one of claims 1-12.
- 25 14. A compound of any one of claims 1-12 for use in treating one or more vasomotor symptoms.
15. The method of claim 13 or the compound of claim 14 wherein one symptom is treated and that symptom is hot flash.
- 30 16. A compound of formula II:

-71-



II;

wherein:

m is 0, 1 or 2;

5 n is 1, 2, 3, 4 or 5;

R is H or methyl provided that if m is 1 or 2, then R must be H and that if m is 0, then R must be methyl;

R^{1a} is H, SO₂CH₃, SO₂(n-C₄-C₆ alkyl), COR², C₁-C₆ alkyl or benzyl;

X¹ is O, CH₂ or C=O;

10 X² is O or NR⁵;

R² is C₁-C₆ alkyl; C₁-C₆ alkoxy; NR⁴R^{4a}; phenoxy; or phenyl optionally substituted with halo;

R⁴ and R^{4a} are independently H, C₁-C₆ alkyl or phenyl;

15 R⁵ is H, C₁-C₆ alkyl or CO₂(C₁-C₆ alkyl); provided that if R^{1a} is H, SO₂(n-C₄-C₆ alkyl) or COR², then X² is NR⁵ and R⁵ is CO₂(C₁-C₆ alkyl); or an acid addition salt thereof.

17. The compound of claim 16 wherein m is 1 or 2 and R^{1a} is SO₂CH₃, benzyl or methyl.

20


18. The compound of claim 16 or claim 17 wherein X² is O.

19. The compound of any one of claims 16-18 wherein X¹ is O or CH₂.

20. The compound of any one of claims 16-19 wherein X^1 is O and m is 1.
21. The compound of any one of claims 16-20 wherein n is 1, 2 or 3.
5. 22. The compound of any one of claims 16-21 wherein n is 1 or 2.
23. The compound of any one of claims 16-22 wherein n is 2 and the corresponding fluoro moieties are at the 3- and 5-positions.
10. 24. The compound of any one of claims 16-22 wherein n is 1 and the corresponding fluoro moiety is at the 4-position.

ABSTRACT

The present invention relates to a selective estrogen receptor modulator of formula I:



5

I;

or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms.

From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

VOY, Gilbert, T.
ELI LILLY AND COMPANY
P. O. Box 6288
Indianapolis, Indiana 46206-6288
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 09 March 2005 (09.03.2005)	
Applicant's or agent's file reference X16604M	IMPORTANT NOTIFICATION
International application No. PCT/US05/000020	International filing date (day/month/year) 18 January 2005 (18.01.2005)
International publication date (day/month/year)	Priority date (day/month/year) 22 January 2004 (22.01.2004)
Applicant ELI LILLY AND COMPANY et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable)* The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable)* An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
22 January 2004 (22.01.2004)	60/538,442	US	21 February 2005 (21.02.2005)
22 January 2004 (22.01.2004)	60/538,342	US	21 February 2005 (21.02.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Fahy Laurence

Facsimile No. +41 22 740 14 35

Facsimile No. +41 22 338 71 30
Telephone No. +41 22 338 9617